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1 MIA - a New Target Protein for Malignant Melanoma Therapy 
 
Abstract 
Malignant melanoma, a malignancy of pigment-producing cells, causes the greatest 
number of skin cancer-related deaths worldwide. The tumor is characterized by its 
aggressive phenotype and can grow deep into the skin at very early stages of the disease. 
After invasion into healthy tissue, melanoma cells can reach the blood and lymphatic 
vessels and spread through the whole body, causing a life-threatening condition. Since 
metastatic lesions are usually characterized by an intrinsic resistance to standard 
chemotherapy, the prognosis of this tumor remains very poor in advanced cases. 
Melanoma inhibitory activity (MIA), an 11 kDa protein expressed and secreted by cells 
after malignant transformation, is known to play a key role in melanoma development, 
progression and tumor cell invasion. After its secretion, which is restricted to the rear pole 
of migrating cells, MIA protein directly interacts with cell adhesion receptors and 
extracellular matrix molecules. By this mechanism, MIA protein actively facilitates focal 
cell detachment from surrounding structures at the cell rear and strongly promotes tumor 
cell invasion and formation of metastases. Analysis at molecular level revealed that MIA 
protein reaches functional activity by self assembly. Functional inactivation of MIA 
protein by dodecapeptides that directly bind to the dimerization interface, leads to a 
strongly reduced tumor cell invasion in an in vivo mouse melanoma model. The molecular 
understanding of the contribution of MIA protein to formation of metastases provides an 
excellent starting point for the development of a new strategy in malignant melanoma 
therapy. 
 
Manuscript in preparation for submission: 
Schmidt J., Bosserhoff A. K.; MIA – a New Target Protein for Malignant Melanoma 
Therapy, 2010; 
 
This introduction will be submitted as a review article once all other chapters of this thesis 
have been accepted for publication 
1 
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1.1 Malignant melanoma – incidence and risk factors 
Malignant melanoma is the most aggressive type of cutaneous cancer originating from 
pigment producing cells in the skin, the melanocytes. This highly invasive tumor is known 
for its uncontrollable growth and for its ability to give rise to metastases into several tissues 
in early stages of the disease. The incidence of malignant melanoma is rising dramatically 
in caucasian populations, with the highest recorded incidence occurring in Australia, where 
the annual rates are 10 and over 20 times the rates in Europe for women and men, 
respectively. High, intermittent exposure to solar UV appears to be a significant risk factor 
for the development of malignant melanoma. 
From an initial phase of radial growth, the tumor may evolve into the more dangerous 
vertical growth phase. In advanced cases, tumor cells acquire a strong potential to 
disseminate. Metastatic lesions are usually characterized by an intrinsic resistance to 
standard chemotherapy representing one of the major causes of the very poor prognosis of 
the tumor. 
The subsequent promotion of detachment of radial and vertical growth phase melanomas 
from basement membrane or matrix proteins serves as a unique progression mechanism for 
melanoma. This exceptionally high migratory potential is probably inherent in these cells, 
since it is also observed during or shortly after neurulation, an embryological event marked 
by neural tube closure. In this process, neural crest cells, including pigment producing 
cells, quickly migrate in succession of migratory stimuli by inhibitory or attractive signals 
to their destination and proliferate there. Nowadays, it has been described that many of the 
genes expressed in melanoma cell lines and melanocytic tumors are required specifically 
during melanoma development, and similar categories of genes are expressed in metastatic 
melanoma and in migratory neural crest cells.1-3 At present, it is discussed whether 
melanoma cells reactivate their strong migratory ability during cancer development.  
However, the molecular mechanisms that are involved in melanoma growth and 
progression are still poorly understood. All previous attempts of targeted therapies, 
although the targets chosen were relevant, did not lead to any success in the treatment of 
melanoma patients. New target molecules in melanoma therapy are strongly needed.  
 
1.2 Facilitation of tumor cell detachment from the pericellular matrix promotes 
invasion and formation of metastases 
To build up metastases in healthy tissues and organs distant from their origin cancer cells, 
released from the primary tumor, spread through blood vessels, lymphatic ducts, or cavities 
2 
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to form colonies. It is a highly dynamic process that essentially depends on the ability of 
cancer cells to detach from the pericellular matrix, migrate, invade intact tissue structures, 
and finally to overcome physiological barriers such as basement membranes upon intra- 
and extravasation. 
Cell migration, physiologically exhibited during wound healing, angiogenesis, embryonic 
development, and immune function, is initiated by migratory stimuli triggered by 
attractants like chemokines and ECM gradients.4 Generally, cells respond by local 
activation and amplification of signaling events facilitating localized actin polymerization 
leading to morphological polarity and establishment of a dominant-leading pseudopodium 
and rear cell body compartment.4-5 Integrin cell adhesion receptors tether the extending 
membrane to the substratum by formation of new focal complexes at the leading front of 
the extending membrane. This adhesion process provides necessary signals to fine-tune 
and maintain directional growth, while retraction mechanisms are suppressed. Cell 
movement then commences as the cell undergoes repeated cycles of membrane extension 
and integrin ligation at the front to provide traction points, and cell body retraction at the 
rear.4, 6 Changes in cell shape occurring during migratory processes are further supported 
by ion channels and aquaporins regulating cell volume by fluctuations.6 Intracellular Ca2+ 
plays a crucial role in almost all cellular processes including regulation of membrane-
fusion as well as cell migration.7-10 By modulating turnover of actin filaments, involvement 
of calpain and recycling of integrins, Ca2+ coordinates different components of the cellular 
migration machinery.11-12 
 
1.3 Clinical relevance and structural analysis of MIA protein 
MIA (melanoma inhibitory activity) protein has been described to play a key role in 
melanoma development and progression.13 In order to identify autocrine growth-regulatory 
factors secreted by melanoma cells, MIA, an 11 kDa protein, strongly expressed and 
secreted by melanocytic tumor cells, was purified from tissue culture supernatant of the 
human melanoma cell line HTZ-19.13-14 In normal skin MIA protein is not detectable. 
Physiologically, it is produced by cartilage and plays a role in chondrocyte 
differentiation.15 Interestingly, MIA expression is induced by UV irradiation, which 
resembles a link between the role of UV in melanoma induction and MIA expression.16 
MIA protein strongly contributes to the invasive and migratory potential of melanoma cells 
and promotes the formation of tumor metastases.13, 17-18 Increased MIA protein plasma 
levels directly correlate with progressive malignancy and a more advanced state of 
3 
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4 
melanocytic tumors.17, 19 Thus, MIA protein serves as a reliable clinical tumor marker to 
detect and monitor metastatic diseases in patients suffering from malignant melanoma.20-21 
In 2001, the three-dimensional structure of the protein was solved by multidimensional 
nuclear magnetic resonance (NMR) and X-ray crystallography techniques.22-23 Structural 
analysis revealed that MIA protein comprises an SH3 domain like fold in solution, a 
structure with two perpendicular, antiparallel, three- and five-stranded beta-sheets.24-25 
MIA represents a novel class of secreted proteins comprising an SH3 domain.26 The MIA 
protein family consists of MIA and the homologous proteins OTOR, MIA-2 and TANGO 
(MIA-3).  
 
1.4 Cellular processing of MIA protein during migration  
The MIA protein transport was found to take the conventional secretion pathway, including 
COPI and COPII mediated vesicle sorting in the endoplasmic reticulum and Golgi 
apparatus, to exit the cell.27 By N-terminal labeling of MIA protein using a HisTag and 
cloning of an N-terminal secretion sequence, the intracellular protein transport was 
followed. Interestingly, the transport along the microtubule system to the cell periphery is 
restricted to the rear of migrating cells (Figure 1).  
 
 
Figure 1: MIA protein transport is restricted to the cell rear of migrating cells 
(A) Cloning strategy (B) After cleavage of the N-terminal secretion sequence, His-tagged MIA protein is 
transported along the microtubule system to the rear of migrating cells. 
 
The final release of MIA protein is a triggered event that depends on an increase in 
intracellular Ca2+ concentration. It was further shown that secretion of MIA protein is 
significantly augmented by KCNN4 potassium channel activity. This channel type was 
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found to be aberrantly expressed in various tumor types and implicated in the promotion of 
cell migration and cell proliferation.28-31 In migrating cells, KCNN4 channel activity was 
detected predominantly at the rear cell pole, which may be due to the intracellular Ca2+ 
gradient in polarized, migrating cells.32 As illustrated in Scheme 1, MIA protein strongly 
contributes to the invasive and migratory potential of melanoma cells by inhibiting 
attachment to extracellular matrix structures including fibronectin, laminin and tenascin in 
vivo.25, 33-34 Following localized protein secretion, a direct interaction of MIA protein with 
cell adhesion receptors integrin 41 and 51 results in locally reduced cell adhesion 
contacts. Formed MIA-integrin-complexes are subsequently internalized into the cell at the 
rear.35 This localized uptake of MIA protein results in focal cell detachment at the cell rear 
and allows a directed cellular movement. Inside the cell these complexes are dissociated 
and MIA protein is degraded in lysosomes, while integrins are recycled and transported to 
the cell front in order to form new adhesion contacts. Changes in metastatic behavior in 
correlation with the expression level of MIA provide evidence that upregulation of MIA 
during malignant transformation of melanocytic cells is causally involved in acquisition of 
the malignant cancer cell phenotype. 
 
Interaction of MIA with 
integrins and ECM molecules 
Active detachment at the 
cell rear mediated by MIA 
Internalisation of MIA-integrin 
complexes 
Degradation of MIA and 
recycling of integrins 
Direction of cell migration 
 
 
Scheme 1: Processing of MIA protein during cellular migration 
MIA protein promotes localized cell detachment at the rear cell pole by modulating integrin activity. By 
directly binding to these cell adhesion receptors and extracellular matrix structures it thus strongly 
contributes to the invasive and migratory potential of melanoma cells. Formed MIA-integrin-complexes are 
subsequently internalized into the cell at the rear pole. This focal cell detachment allows a directed cell 
movement. Inside the cell MIA-integrin complexes are dissociated, MIA protein is degraded in acidic 
vesicles while integrins are recycled and transported to the cell front in order to form new adhesion contacts.  
 
1.5 Functional inhibition of MIA protein 
NMR spectroscopy and Western blot analysis revealed that MIA protein has a tendency to 
build homomeric assemblies with head-to-tail linkages. By functionally analyzing MIA 
protein mutant forms in vitro it was demonstrated that MIA protein achieves activity by 
5 
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self assembly.36 Monomeric species are completely inactive, suggesting that the binding 
site for integrins, probably generated by protein assembly, could be located at the surface 
involving both MIA subunits. Inactivation of MIA protein by peptidic dimerization 
inhibitors provides an excellent starting point for the development of a new inhibitory 
strategy to reduce tumor cell invasion and formation of metastases. To selectively screen 
for substances that directly bind to the MIA protein dimerization domain and thus generate 
inactive monomers, a transition metal based fluorescence polarization assay was 
established.37 AR71, a dodecapeptide identified in this screening assay, was analyzed for 
its MIA inhibitory potential in vitro and in vivo studies. Binding to the dimerization 
domain was confirmed by NMR-spectroscopy. Interestingly, inhibition of MIA protein 
function in the in vivo mouse melanoma model led to strongly reduced numbers of 
metastases in mice being treated with daily iv injections of peptide AR71 as shown in 
Figure 2.36 Based on these data, the rational design and development of a novel 
pharmacophore which inhibits MIA protein dimerization may provide a key element in 
malignant melanoma therapy. 
 
 
Figure 2: Dodecapeptide AR71 strongly reduces formation of melanoma metastasis in vivo 
Wild type murine B16 melanoma cells were injected into the spleen of Bl/6N mice with the mice being 
subsequently treated with i.v. injections of AR71. Histological analyses revealed a significant reduction of 
metastases in the liver of mice treated with AR71 compared to the liver of untreated control mice. 
 
1.6 Antimetastatic agents as a new therapy strategy 
Conventional chemotherapy treatments target all fast dividing cells and thus 
indiscriminately kill cancer cells as well as hair follicle cells and cells in the mucous 
membranes in the gastrointestinal tract. By targeting MIA protein, which is only expressed 
control 
AR71 
Liver with 
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Liver 
Spleen with 
primary tumor 
Spleen with 
primary tumor 
 
1   MIA - a New Target Protein for Malignant Melanoma Therapy 
in malignant melanoma and in early-phase differentiating chondrocytes, the expected side 
effects of treatment with MIA inhibitory compounds should be minimal. Side effects on 
cartilage are not expected as MIA-deficient mice show no phenotype.38 Next to cytotoxic 
compounds and angiogenesis inhibitors, a MIA inhibitor will present a novel antimetastatic 
therapeutic strategy of cancer treatment. Only in rare cases the primary tumor is fatal for 
patients suffering from malignant melanoma. Mostly, the cause of death is the failure of 
vital organs due to the formation of metastases. Development of antimetastatic agents 
could be of great importance and a milestone in the treatment of malignant melanoma. 
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2 Directed, Migration-associated Secretion of Melanoma Inhibitory 
Activity (MIA) at the Cell Rear is supported by KCNN4 Potassium 
Channels 
 
Abstract 
Malignant melanoma, characterized by invasive local growth and early formation of 
metastases, is the most aggressive type of skin cancer. Melanoma Inhibitory Activity 
(MIA), secreted by malignant melanoma cells, interacts with the cell adhesion receptors 
integrin 41 and 51, facilitating cell detachment and promoting formation of 
metastases. In the present study, we demonstrate that MIA secretion is confined to the rear 
end of migrating cells, while in non-migrating cells MIA accumulates in the actin-cortex. 
MIA protein takes a conventional secretory pathway including COPI- and COPII-
dependent protein transport to the cell periphery, where its final release depends on 
intracellular Ca2+ ions. Interestingly, the Ca2+-activated potassium channel KCNN4, known 
to be active at the rear end of migrating cells, was found to support MIA secretion. 
Secretion was diminished by the specific KCNN4 channel inhibitor TRAM-34 and by 
expression of dominant-negative mutants of the channel. In summary, we have elucidated 
the directed, migration-associated transport of MIA protein to the cell rear and disclosed a 
new mechanism by which KCNN4 potassium channels promote cell migration. 
 
The results of this chapter have been submitted for publication: 
Schmidt J., Friebel K., Schönherr R., Coppolino M. G., Bosserhoff A. K.; Directed, 
Migration-associated Secretion of Melanoma Inhibitory Activity (MIA) at the Cell Rear is 
supported by KCNN4 Potassium Channels. Cell Res  2009; (submitted) 
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2.1 Introduction 
Previously, melanoma inhibitory activity (MIA) has been identified as an 11 kDa protein 
physiologically produced by cartilage and strongly expressed and secreted by malignant 
melanoma cells.1-2 MIA protein is known to play a key role in melanoma development, 
progression and formation of metastasis.2-3 Increased MIA protein plasma levels directly 
correlate with progressive malignancy and a more advanced state of melanocytic tumors.1, 4 
Thus, MIA protein serves as a reliable clinical tumor marker to detect and monitor 
metastatic disease in patients suffering from malignant melanoma.1, 5-6 MIA protein 
strongly contributes to the invasive and migratory potential of melanoma cells and 
promotes the formation of tumor metastases; however, the mechanistic link between MIA 
protein and cell motility remains unclear.2 Recent data describe a direct interaction of MIA 
protein with cell adhesion receptors integrin 41 and integrin 51 followed by 
facilitation of cell detachment.7 Cell migration requires adhesion to the extracellular matrix 
to provide traction points and to stabilize protrusions at the cell front. Conversely, 
retraction of the rear cell end demands the release of adhesion contacts. In line with this 
assumption, external addition of MIA protein does not support migration but results in 
unpolarized cell detachment and reduced invasiveness in Boyden chamber assays.2 To 
account for the promigratory effect of endogenously expressed and secreted MIA protein, 
we proposed that MIA secretion is directed to the rear end of a migrating cell where it can 
bind to integrins and thereby promote cell retraction.7 MIA-integrin complexes are 
subsequently internalized at the rear of the cell.8 
The MIA secretion pathway has not yet been analyzed in detail, but the protein comprises a 
typical N-terminal ER-signal peptide that is processed during synthesis.9 In the 
conventional secretory pathway, protein synthesis at the ER is followed by its translocation 
to the Golgi apparatus via COPII-coated vesicles. Further protein sorting in the Golgi 
depends on the formation of COPI-coated vesicular intermediates, which mediate 
retrograde movement of components in the Golgi and back to the ER as well as 
anterograde movements to the cell membrane.10 Following vesicle tethering, docking and 
membrane fusion, the cargo proteins are released into the extracellular space. The final 
release can either be a constitutive process or a triggered event that depends on an increase 
in intracellular Ca2+ concentration. Both scenarios involve N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) protein complexes to mediate vesicle docking 
and fusion.11 
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Intracellular Ca2+ plays a crucial role in almost all cellular processes; including regulation 
of membrane-fusion as well as cell migration.12-13 By modulating turnover of actin 
filaments, activation of calpain mediating release of cell-matrix contacts and recycling of 
integrins, Ca2+ coordinates different components of the cellular migration machinery.14-17 
Another player linking intracellular Ca2+ ions and cell migration is the calcium-activated 
potassium channel KCNN4. This channel type was found to be aberrantly expressed in 
various tumor types and implicated in the promotion of cell migration and cell 
proliferation.18-21 In migrating cells, KCNN4 channel activity was detected predominantly 
at the rear cell pole, which may be due to the intracellular Ca2+ gradient in polarized, 
migrating cells.22 While it was shown that specific inhibition of KCNN4 channels reduces 
cell migration, the underlying mechanisms are still largely elusive.23-25  
Here, we used a HisTag-labeled MIA protein construct to monitor MIA secretion in 
melanoma cells. We show that in migrating cells, MIA secretion is restricted to the rear of 
the cell. This could be crucial for the mechanism through which MIA contributes to 
migration. Experiments using specific inhibitors and dominant negative mutants revealed 
that MIA follows a conventional secretion pathway, involving COPI- and COPII-
dependent protein transport to the cell periphery, where the final release depends on 
intracellular Ca2+ ions. Further, we show that secretion of MIA protein is significantly 
augmented by KCNN4 potassium channel activity. In summary, we provide experimental 
evidence for our model, first hypothesized in 2006, of facilitated retraction at the rear of 
migrating cells controlled in part by directed secretion of MIA protein.7 
 
2.2 Results 
2.2.1 Targeted MIA protein transport to the rear of migrating cells  
We aimed to elucidate the MIA protein secretion pathway to further understand the 
contribution of MIA protein to the enhanced migratory ability of melanoma cells. To 
follow MIA protein transport and distribution in migrating and non-migrating cells we 
visualized MIA protein by transiently transfecting Mel Im cells with a His-tagged MIA 
protein-containing expression plasmid. The MIA-HisTag conjugate was visualized in 
immunofluorescence studies using primary anti-HisTag and fluorescently labeled 
secondary antibodies. To verify the direction of migration, we co-stained the Golgi 
apparatus, since it is generally known that in migrating cells reorientation of the MTOC 
repositions the Golgi apparatus toward the leading edge of the cell and contributes to 
directional cell migration.26 Figure 1A presents Mel Im cells that were co-transfected with 
13 
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pCMX-PL1-hMIA-HisTag and Golgi-GFP (endomannosidase) plasmids to monitor 
intracellular MIA protein distribution. In polarized migrating cells MIA protein is 
asymmetrically distributed at one cell pole as shown in Figure 1A,(A). Deduced from the 
localization of the Golgi on the side of the nucleus towards the leading edge in migrating 
cells Figure 1A,(B), we conclude that MIA protein is transported to the rear cell pole 
(Figure 1A,(C)). Compared to migrating cells, non-polarized, non-migrating cells show a 
homogeneous distribution of MIA protein in the cytoplasm, as illustrated in Figure 1B. 
Interestingly, MIA protein appears to accumulate at the actin cortex, possibly in a vesicle 
pool as shown in Figure 1B,(A) and (D) using the two melanoma cell lines Mel Im and Mel 
Ju.  
To further analyze the involvement of the actin cytoskeleton in secretion of MIA protein, 
we tested the effect of Jasplakinolide, which induces actin-polymerization. Exposure of 
cells to 5 nM and 50 nM Jasplakinolide results in a decrease of about 20% to 30% in the 
amount of secreted MIA protein, respectively, compared to the corresponding DMSO 
control (data not shown). These observations indicate involvement of the actin network in 
MIA protein transport towards the cell rear. 
 
 
A 
Golgi-GFP MIA HisTag Merge 
A B C 
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Figure 1: Targeted MIA protein transport to the cell rear in migrating cells  
(A) Mel Im cells were co-transfected with pCMX-PL1-hMIA-HisTag and Golgi-GFP (endomannosidase) 
plasmids to detect intracellular MIA protein distribution and define direction of movement. In polarized 
migrating cells MIA protein is asymmetrically distributed at one cell pole, indicated by the white arrow (A). 
The Golgi apparatus is reoriented toward the leading edge of the cell during migration (B). (C) In migrating 
cells MIA protein is transported to the cell rear. (B) Adhered, non-polarized and non-migrating cells 
transiently transfected with pCMX-PL1-hMIA-HisTag construct show a homogeneous distribution of MIA 
protein in the cytoplasm. At the actin cortex MIA protein accumulates in a vesicle pool as indicated by white 
arrows in (A) for Mel Im cells and in (D) for Mel Ju cells. All experiments were performed at least in 
triplicates. 
 
2.2.2 Intracellular transport of MIA protein follows the conventional secretory 
pathway  
To characterize the MIA protein secretion pathway more closely, we analyzed whether 
MIA protein is transported through the conventional secretory pathway or if it takes an 
unconventional route to the cell surface in a Golgi-independent manner. Cells were treated 
with the fungal metabolite Brefeldin A, which blocks the recruitment of the ADP-
ribosylation factor ARF1 to the Golgi, impairing the formation of COP I-coated vesicles 
and ultimately inhibiting ER-to-Golgi transport.27 Cells were also exposed to Exo-1, which 
inhibits traffic emanating from the ER by inducing rapid collapse of the Golgi into the ER. 
After cell treatment with these compounds, the MIA protein concentration in cell culture 
supernatant was determined by MIA-ELISA. The DMSO or H2O control, respectively, 
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was set to 100%. BFA at concentrations of 3.5 µM and 7.0 µM almost completely inhibits 
MIA protein secretion in both Mel Im and Mel Ju cells (Figure 2A). Treatment of cells 
with Exo1 at a concentration of 50 µM and 100 µM significantly reduced MIA protein 
secretion. Figure 2B presents the corresponding immunofluorescence analysis of the MIA 
protein. It demonstrates that migrating Mel Im cells, transiently transfected with a pCMX-
PL1-hMIA-HisTag vector and treated with 7 µM BFA, showed an altered distribution of 
MIA protein. To delineate cell boundaries, the actin cytoskeleton was stained with 
rhodamine-phalloidin. The control cells show MIA protein distribution at the cell rear 
(Figure 2B,(A)). In the overlay of MIA protein and actin filament staining in Figure 2B,(C) 
it is clearly visible that the MIA protein is delivered into the tip of the rear cell edge. After 
treatment of Mel Im cells with BFA, MIA protein accumulates proximal to the nucleus 
(Figure 2B,(F)). Cells were also transiently transfected with a dominant negative Sar1p 
(H79G) construct or mock transfected as controls. Sar1p is a small ER-associated GTPase, 
necessary for COPII-dependent vesicle formation at the ER.28-31 As shown in Figure 2C, 
overexpression of the dominant-negative Sar1p mutant (H79G) leads to a reduction of 
MIA protein secretion relative to mock control, indicating that ER exit of MIA protein is 
mediated by COP II-coated vesicles.  
We further confirmed microtubule based transport of MIA protein by treatment of 
melanoma cells with 25 µM and 50 µM Nocodazole, which leads to depolymerization of 
microtubules, and 1 mM and 2 mM AMP-PNP, a non-hydrolysable analogue of adenosine 
5’-triphosphate which blocks the ATP-dependent microtubule motor protein kinesin.32 
Both compounds reduce MIA protein exocytosis in a dose dependent manner (Figure 2D). 
Immunofluorescence analysis of Mel Im cells treated with the kinesin family inhibitor 
AMP-PNP at a concentration of 2 mM revealed a perturbed distribution of MIA protein: it 
is delivered to the cell rear, but it is not visible at the rear tip of the cell, suggesting that the 
peripheral microtubule based MIA protein transport has been interrupted (Figure 2B,(I)). 
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Figure 2: ER and Golgi-dependent MIA protein sorting and microtubule-based transport to the rear cell 
pole (A) Mel Im cells and Mel Ju cells were treated with BFA and with Exo1, both inhibiting the ER-Golgi 
transport. BFA at a concentration of 3.5 µM and 7.0 µM almost completely inhibits MIA protein secretion in 
both cell lines. Treatment of cells with Exo1 at a concentration of 50 µM and 100 µM significantly reduces 
MIA protein exocytosis compared to the respective H2O or DMSO control. (B) Immunofluorescence 
analysis of Mel Im cells that were transiently transfected with a pCMX-PL1-hMIA-HisTag plasmid and 
stained for MIA protein using a mouse anti-HisTag antibody and a FITC-labeled anti mouse secondary 
antibody, were treated with 7 µM BFA and AMP-PNP at a concentration of 2 mM. For a better illustration of 
cell borders an actin staining was performed in addition. Inhibition of ER-to-Golgi-transport by BFA 
treatment results in an accumulation of MIA protein in close proximity to the nucleus (F). Exposure to AMP-
PNP, the vesicle transporter protein inhibitor, leads to a characteristic distribution of MIA protein, which is 
delivered to the cell rear, but it is not visible at the rear tip of the cell since the peripheral microtubule based 
MIA protein transport is interrupted (I). In contrast, in the untreated control cells MIA protein is delivered 
into the rear cell tip (C), as indicated by the white arrows. (C) Cells that were transiently transfected with a 
dominant negative Sar1p (H79G) construct show a reduction of MIA protein secretion relative to mock 
control. (D) To investigate microtubule involvement in MIA protein secretion, melanoma cells were treated 
with 25 µM and 50 µM Nocodazole, and 1 mM and 2 mM AMP-PNP. Both compounds reduce MIA protein 
exocytosis in a dose dependent manner. All experiments were performed at least in triplicates. 
 
2.2.3 MIA protein secretion is a Ca2+-regulated process  
It is generally accepted that migrating cells are polarized along their axis of movement and 
establish an intracellular Ca2+ gradient with a lower Ca2+ concentration at the cell 
front.14-15, 17 By mediating salt efflux or influx, followed by osmotic water flow, ion 
channels and transporters play a pivotal role in regulating cell volume during migration. 
These considerations apply in particular to the KCNN4 channel, which is activated in 
migrating cells by increased Ca2+, especially at the cell rear.17, 22, 33 Since KCNN4 channel 
expression was observed in malignant melanoma cells we decided to test for KCNN4-
mediated potassium currents in Mel Im cells and to investigate whether there is a direct 
association of channel activity and MIA-protein secretion.20 Figure 3A shows a typical 
current response of Mel Im cells to a voltage ramp ranging from -100 mV to +50 mV in 
the whole-cell patch clamp configuration. Bath application of the KCNN4-specific channel 
blocker TRAM-34 resulted in a rapid decrease of the current amplitude (Figure 3A,B), 
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indicating that this channel is in fact in an active state.34 The residual current is most likely 
due to other ion channels present in this cell line. At least in part, this remaining current is 
not carried by potassium-selective channels, as indicated by right-shifted reversal 
potentials in the presence of TRAM-34. 
The above results prompted us to analyze whether inhibition of the KCNN4 channel by 
TRAM-34 impacts MIA protein distribution. In the cytoplasm of Mel Im cells that were 
transiently transfected with His-tagged MIA protein, treatment of migrating cells with 
TRAM-34 did not prevent transport of MIA protein to the cell rear. In these treated cells, 
however, the MIA protein accumulated at the plasma membrane as shown by white arrows 
in Figure 3C,(F).  
 
B A 
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Figure 3: MIA protein secretion is a Ca2+-regulated process  
(A) Verification of active KCNN4 channels in Mel Im cells. Representative current traces in response to 
voltage ramps from -100 mV to +50 mV, recorded before (black) and after (red) application of 200 nM 
TRAM-34. (B) Time course of KCNN4 inhibition by TRAM-34. The percentage of remaining current is 
plotted as a function of time. The start of TRAM-34 application is indicated by the arrow. The continuous 
line describes the time course of channel block according to a single exponential function. Data points with 
filled circles correspond to current traces shown in panel B. (C) The corresponding immunofluorescence of 
Mel Im cells transiently transfected with pCMX-PL1-hMIA-HisTag and treated with 40 µM TRAM-34 
revealed an accumulation of MIA protein at the cell membrane, as indicated by the white arrow (F). In the 
corresponding control cells (C), MIA protein, transported to the rear cell tip, is homogeneously distributed in 
the cytoplasm, (shown by white arrows). Experiments were performed at least in triplicates. 
 
To address the functional impact of KCNN4 channel activity on MIA protein secretion, we 
investigated the effects of treatment with activators and inhibitors as well as dominant-
negative constructs of the KCNN4 channel. As shown in Figure 4A, activation of the 
KCNN4 channel by 100 µM and 200 µM 1-EBIO leads to a small increase of MIA protein 
secretion, suggesting that these channels are already in the active state. Mel Ju cells, which 
display a weaker tendency to migrate compared to Mel Im cells, showed a larger increase 
in MIA protein secretion after KCNN4 channel activation. Inhibition of the KCNN4 
channel either by treatment with TRAM-34 at concentrations of 20 µM and 40 µM or after 
transfection with two different dominant-negative mutant forms of the KCNN4 channel, 
dnKCNN4 Y253L and dnKCNN4 AAA, significantly decreased MIA protein secretion 
C 
Control
A B C 
TRAM-34 
(40 µM) 
 
D E F 
MIA HisTag Actin Merge 
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(Figure 4B).35 The dominant-negative KCNN4 constructs encode channel subunits with 
mutations in the potassium selectivity filter. Upon tetrameric coassembly with wild-type 
subunits they generate nonfunctional channels. To confirm the dominant negative activity 
of the mutant KCNN4 constructs, HEK293 cells were transfected with the wild-type 
expression construct alone, or in combination with increasing amounts of dominant 
negative KCNN4 constructs (Figure 4C,D). Both dnKCNN4 constructs decreased the 
mean potassium currents at least 70-fold upon transfection in 4:1 ratio to wild-type 
KCNN4. Mock-transfected HEK293 cells did not exhibit any calcium-activated potassium 
currents (not shown).  
To further assess the direct association between MIA protein secretion and expression of 
the KCNN4 channel, we transiently co-transfected HEK293 cells (which normally express 
neither MIA protein nor KCNN4 channels) with a MIA protein-containing plasmid, 
pCMX-PL1-hMIA, a KCNN4 channel-containing plasmid, and with the dominant-negative 
KCNN4 construct (dnKCNN4 AAA), using a range of amounts of the different vectors 
(Figure 4E). Co-transfection of MIA protein and KCNN4 channel containing vectors 
increased MIA protein secretion approximately 40% relative to cells that were transfected 
with a MIA protein-containing vector alone. This effect could be reduced in a dose 
dependent manner to the level of the control by co-transfection of cells with 
dnKCNN4 AAA, the mutant form of the KCNN4 channel. This observation clearly 
represents a direct association of MIA protein secretion and KCNN4 channel activity. 
Since the KCNN4 channel activity is increased by an elevation in the intracellular 
Ca2+ concentration, we also examined the influence of Ca2+ on MIA protein secretion. This 
is of particular interest, since the Ca2+ concentration is elevated at the rear of migrating 
cells, where MIA protein is also secreted. Treatment of cells with 1 µM and 5 µM 
BAPTA-AM, a membrane permeable, selective chelator of intracellular Ca2+, leads to a 
significant decrease in MIA protein secretion in a dose dependent manner (Figure 4F).36 
Additionally, we incubated Mel Im and Mel Ju cells with 1 nM and 10 nM Calcimycin 
(A23187), an ionophore that is highly selective for Ca2+ ions leading to an elevation of the 
intracellular Ca2+ concentration.37 Interestingly, the amount of MIA protein secreted into 
the cell culture supernatant increased by 20% compared to DMSO-treated control cells. All 
these results strongly argue for a KCNN4 channel associated regulated MIA protein 
secretion. 
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Figure 4: MIA protein secretion is associated to KCNN4 channel activity 
(A) Mel Im and Mel Ju cells were treated with 100 µM and 200 µM 1-EBIO, a KCNN4 channel activator, 
and with 20 µM and 40 µM TRAM-34, a specific inhibitor of the KCNN4 channel. Activation of the KCNN4 
channel by 1-EBIO results in a small increase of MIA protein secretion, suggesting that the KCNN4 channel 
is already in an active state. Inhibition of the KCNN4 channel by TRAM-34 leads to a significant reduction 
in MIA protein secretion. (B) Mel Im and Mel Ju cells were transiently transfected with two different 
dominant negative mutant forms of the KCNN4 cannel, dnKCNN4 Y253L and dnKCNN4 AAA. Compared 
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to the mock control, these treated cells show a significant reduction in MIA protein secretion in both cases. 
(C, D) Verification of dominant-negative activity of dnKCNN4 Y253L (C) and dnKCNN4 AAA (D). 
HEK293 cells were transfected with the wild-type KCNN4 expression construct alone (IK), or in 
combination with increasing amounts of dominant negative constructs. Current densities are presented as box 
and whisker plots. Medians are indicated in red. Boxes range from 25-75% of all data points. Whiskers 
indicate the lowest and highest current densities. The numbers of individual experiments are indicated in 
parenthesis. (E) To better demonstrate the direct association of MIA protein secretion and the expression of 
the KCNN4 channel, HEK293 cells, which normally neither express MIA protein nor KCNN4 channels, 
were transiently co-transfected with pCMX-PL1-hMIA, a KCNN4 channel containing plasmid and with the 
dominant negative construct of the KCNN4 channel dnKCNN4 AAA with varying vector amounts. Co-
transfection of MIA protein and KCNN4 channel containing vectors leads to an increase of MIA protein 
secretion of about 40% relative to MIA protein exocytosis of cells, which were transfected with a MIA 
protein containing vector pCMX-PL1-hMIA alone. This effect can be reduced to the level of the control by 
co-transfection of cells with the dnKCNN4 AAA mutant form of the KCNN4 channel, in a dose dependent 
manner. (F) The influence of intracellular Ca2+ concentration on MIA protein secretion was investigated by 
exposure of Mel Im and Mel Ju cells to 1 nM and 10 nM Calcimycin (A23187) and 1 µM and 5 µM 
BAPTA-AM. Relative to cell culture supernatant from DMSO treated control cells, the secreted MIA protein 
amount increases up to 120% after Calcimycin treatment, while exposure to BABTA-AM results in a 
significant decrease in MIA protein secretion. Experiments were performed in triplicates. 
 
2.3 Discussion 
In the present study we elucidated the secretory pathway of MIA protein, which was 
previously identified to play a key role in the formation of metastases in malignant 
melanoma. MIA protein was described to directly interact with cell adhesion receptors 
integrin 41 and integrin 51 as well as with extracellular matrix molecules including 
fibronectin, tenascin and laminin.2, 7 As a result, matrix structures surrounding the cell and 
integrin adhesion molecules are masked by MIA protein, which consequently impacts 
melanoma cell attachment. Thus, we proposed that the contribution of MIA protein to the 
enhanced invasive capacity of malignant melanoma cells can be ascribed to a mechanism 
requiring targeted MIA protein transport and secretion. To enable a tumor cell to migrate 
in a defined direction, localized cell detachment is a prerequisite and could be achieved by 
directed MIA protein transport to the cell rear followed by localized MIA protein 
exocytosis. Based on this proposal, we have now investigated the secretion pathway of 
MIA protein and for the first time describe a targeted, migration-associated transport of a 
secretory protein to the rear cell pole.  
 
Induction of cell migration triggers directed MIA protein delivery to the rear cell pole  
Non-polarized and non-migrating cells show a homogeneous distribution of MIA protein 
in the cytoplasm. After external stimuli the initial response of a cell is to polarize, meaning 
that molecular processes at the cell front differ from that at the cell rear. The cell starts to 
extend protrusions at the leading edge which are stabilized by adhesion to the extracellular 
matrix. These adhesion contacts serve as traction points for migration and initiate signals 
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that regulate adhesion dynamics and trailing edge retraction. Dynamic responses that drive 
migration are dependent on a highly organized cytoskeleton function.  
In polarized control cells, we clearly defined the direction of migration by staining both the 
MIA protein and the Golgi apparatus, which, together with the MTOC, is reoriented 
toward the leading edge. Thus, we were able to follow MIA protein delivery to the rear cell 
pole. Generally, migration is initiated in response to extracellular stimuli. Required cell 
polarity is mediated by a set of interlinked positive feedback loops. Following the 
increased activity of Rho-family GTPases, integrins form focal adhesions, and 
subsequently phosphoinositide 3-kinases, microtubules, vesicular transport and other 
factors are involved.38 The fine regulation of the actin cytoskeleton presupposes complex 
control mechanisms to ensure coordinated migration, which can be turned on and off by 
the cell on the requirements of a given situation.39 At this time, the molecular details of the 
initiation of migration are not completely understood. Upon examining 
immunofluorescence staining of migrating cells, we deduced that regulation of directed 
MIA protein transport is critical to the intricate process of initiating migration. The 
characteristic unidirectional MIA protein distribution is clearly visible, even if the MIA 
protein transport is perturbed by treatment with AMP-PNP or TRAM-34, respectively. 
This observation of specifically targeted MIA protein secretion agrees well with data 
established in previous studies that demonstrate an uptake of MIA protein-integrin 
complexes at the cell rear of migrating cells and thus strongly supports our hypothesis.8  
Our findings suggest that exocytic vesicles containing MIA protein take the conventional 
secretory pathway to the cell exterior. MIA contains an amino-terminal signal peptide that 
directs its translation into the ER. Afterwards, it is transported through the ER-Golgi 
pathway of protein export involving COP II and COP I coated vesicles. Mediated by the 
motor protein kinesin, MIA protein-containing secretory vesicles are transported along the 
microtubule system. After transport through the dense meshwork of actin filaments, MIA 
protein reaches the plasma membrane at the cell rear where it is finally exocytosed. 
 
MIA protein secretion is a Ca2+ regulated process and is directly associated with KCNN4 
channel activity  
We determined that MIA protein secretion is a Ca2+-regulated process, similar to the 
previously described secretion of many other specialized exocytic vesicles such as 
azurophile granules in neutrophils, specific granules in mast cells and lytic granules in 
cytotoxic T-lymphocytes.40-43 The most thoroughly characterized Ca2+-triggered exocytosis 
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is the release of neurotransmitters into the synaptic space.44 Elevation of intracellular Ca2+ 
levels induces vesicle docking and fusion events at the plasma membrane mediated by 
SNARE proteins. In addition to these fusion events, several other factors involved at 
different stages of the secretory pathway are reported to be potential Ca2+ targets during the 
regulation of neurotransmitter release; for example, protein kinases as well as other 
Ca2+-regulated proteins like rabphilin; -actinin and -adductin, which are involved in 
regulation of actin filament organization.45-47 Here, we show that in the meshwork of actin 
filaments a pool of MIA protein-containing secretory vesicles is stored and is only visible 
in adherent, non-migrating melanoma cells. Interestingly, intracellular Ca2+ has also been 
found to be responsible for the recovery of the storage pool following neurotransmitter 
release.48 
Intracellular Ca2+ plays a fundamental role in regulating cellular events and signaling. Cell 
migration is a process that strongly depends on intracellular Ca2+, including the influences 
that Ca2+ has on volume-regulating mechanisms. Cell volume, which is subjected to 
fluctuations that are related to permanent cell shape changes, increases during protrusion of 
the lamellopodium at the cell front and decreases during retraction of the rear cell 
body.49-50 In addition to setting the cell volume, intracellular Ca2+ modulates the turnover 
of actin filaments; an elevation of Ca2+ promotes actin depolymerisation, whereas a low 
Ca2+ concentration favors actin polymerization. The regulation of the cytoskeletal 
migration machinery is supported by the intracellular gradient of Ca2+ with the higher 
concentration at the cell rear.14-15, 17 Another relevant factor for the motility of cells is the 
Ca2+-controlled function of calpains in the release of cell-extracellular matrix contacts at 
the cell rear.16 Subsequently, this release is then followed by the recycling of integrins.51 
Further, the contraction of the rear cell body by Ca2+-regulated phosphorylation of myosin 
light chain is an important step during migration.52 The close relationship between 
intracellular Ca2+ ion concentration and cell migration-promoting processes strongly 
suggests a crucial role for ion channel activity. Since Ca2+-activated K+ channels are 
expressed in most (if not all) cells possessing the ability to migrate, including leukocytes 
and many tumor cells, their role in cell migration warrants close examination.18, 53-59 In 
previous studies, it was described that the KCNN4 channel is highly expressed in 
malignant melanoma cells.20 Ion fluctuations mediated by the KCNN4 channel are known 
to play a fundamental role in cell migration, since specific inhibition or activation of this 
ion channel results in impaired cell mobility.25, 60-63 Interestingly, it was also reported that 
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the KCNN4 channels are only active at the rear cell pole of migrating cells due to the 
intracellular Ca2+ gradient. At the cell front KCNN4 channels appear to be inactive.22, 63  
 
The results described here are consistent with the observation of Ca2+-regulated secretion 
of MIA protein at the cell rear and support a model that underlines the pivotal function of 
MIA protein in promoting directed migration. A migratory stimulus leads to elevation in 
intracellular Ca2+ concentration, which activates the KCNN4 channel and functions as a 
signal amplifier causing hyperpolarization of the cell membrane, thus leading to an 
enhanced electrochemical driving force for Ca2+ influx.19, 64 Since these ion channels are 
mainly active at the cell rear, the increase in intracellular Ca2+ promotes cell migration by 
several mechanisms mentioned above and simultaneously induces fusion of MIA protein 
containing secretory vesicles with the plasma membrane at the rear cell pole. While 
KCNN4 activity clearly facilitates MIA secretion, it is not an indispensable prerequisite for 
the secretion process, neither in melanoma cells nor in transfected HEK293 cells. It is 
important to mention that our experimental strategies, used to eliminate KCNN4 function, 
do not remove the channel complexes, but rather interfere with the pore function. For the 
voltage-gated potassium channel Kv2.1 (KCNB1) it was recently shown that it facilitates 
exocytosis in PC12 chromaffin cells by direct interaction with the SNARE protein 
syntaxin, independently of the functional pore.65 While a direct interaction of KCNN4 with 
the export machinery may not be excluded at this time, its function in MIA exocytosis does 
require potassium efflux through the channel pore.  
Once MIA is exocytosed at the cell rear, it is able to mask extracellular matrix structures 
and facilitate cell detachment through a direct interaction with cell adhesion receptors 
integrin 41 and integrin 51. While at the rear pole cell-extracellular matrix contacts 
are detached followed by internalization of MIA protein-integrin-complexes, at the cell 
front recycled integrins are exocytosed at the surface allowing new cell-ECM contacts to 
form. Thus, migration-associated MIA protein secretion at the cell rear strongly supports 
directed cell movement and helps to explain the aggressive migratory behavior and 
metastatic potential of malignant melanoma cells. 
 
2.4 Materials and Methods 
Cell lines and cell culture conditions  
The melanoma cell line Mel Im, established from a human metastatic bioptic sample 
(generous gift from Dr. Johnson, University of Munich, Germany), was used in almost all 
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experiments. Additionally, main experiments were also conducted using the human cell 
line Mel Ju, which was derived from metastases of malignant melanoma. HEK293 cells 
were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). All cells were maintained in DMEM (PAA Laboratories GmbH, 
Austria) supplemented with penicillin (400 U/mL), streptomycin (50 µg/mL), l-glutamine 
(300 µg/mL) and 10% fetal calf serum (Pan Biotech GmbH, Germany) and split in 
1:5 ratio every 3 days. 
 
MIA secretion assay  
2.5 x 105 cells per mL were seeded in 6-well plates (Corning Omnilab, Germany) and 
cultured in 2 mL of Dulbecco’s modified Eagle’s medium (PAA, Germany) with 10% fetal 
calf serum (Pan, Germany). Cells were treated with various inhibitory compounds (all 
purchased from Sigma Aldrich, Germany) in different final concentrations: 3-(4-
fluorobenzoylamino)-benzoic acid methyl ester (Exo1) was used at a final concentration of 
50 µM and 100 µM, Brefeldin A (BFA) at 3.5 µM and 7 µM, Nocodazole at 25 µM and 
50 µM, Jasplakinolide was used at 5 nM and 50 nM, adenosine 5’-(,-imido)triphosphate 
tetralithium salt hydrate (AMP-PNP) at 1 mM and 2 mM, 1,2-bis(2-aminophenoxy)ethane-
N,N,N’,N’-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM) at 1 µM and 5 µM, 
Calcimycin (A23187) at 1 nM and 10 nM, 1-ethly-2-benzimidazolinone (1-EBIO) at 
100 µM and 200 µM and 1-[(chlorophenyl)diphenylmethyl]1-H-pyrazole (TRAM-34) was 
used at a final concentration of 20 µM and 40 µM. Except AMP-PNP, which was 
dissolved in H2O, all compounds mentioned above were dissolved in DMSO, which was 
also used in the corresponding control experiment. After treatment cells were incubated for 
8 h at 37°C and 8% CO2. Afterwards, the cell culture supernatant was collected for 
quantification of secreted MIA protein using an ELISA system (Roche Applied Science, 
Germany). Monoclonal antibodies conjugated with biotin or peroxidase, respectively, were 
used to quantify MIA protein in a 96-well plate coated with streptavidin. 2,2’-azino-di[3-
ethylbenzthiazoline sulfonate] (ABTS) was used as substrate and measured at 405 nm 
using a fluorescence microplate reader (Emax precision microplate reader, Molecular 
Devices). 
 
MIA-HisTag and dnKCNN4 plasmid construction  
MIA HisTag expression plasmid was created by PCR amplification of human melanoma 
cDNA using the MJ Research PTC-200 Peltier Thermo Cycler (BioRad). The cDNA was 
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generated from RNA isolated from the melanoma cell line Mel Im using the total RNA Kit 
(Omega Biotech, USA) followed by reverse transcription using superscript (Invitrogen, 
Germany). The HisTag sequence was inserted between the hydrophobic signal-peptide 
sequence responsible for transport into the endoplasmatic reticulum and the MIA sequence 
according to the site-directed mutagenesis by overlap extension (SOE)-method using the 
primers 5’- GAC GAA TTC ATG GCC CGG TCC CTG GTG - 3’ and 5’- CAT AGG 
ACC ACC GTG ATG GTG ATG GTG ATG GTG ATG CCT GAC ACC AGG -3’ for the 
signal-peptide-HisTag fragment and 5’- CCT GGT GTC AGG CAT CAC CAT CAC CAT 
CAC CAT CAC GGT GGT CCT ATG -3’ and 5’- GAC AAG CTT TCA CTG GCA GTA 
GAA ATC CCA -3’ for amplification of HisTag-MIA fragment.66 After fusion of these 
two fragments and digestion of the resulting PCR product with EcoRI and HindIII (NEB, 
Germany) this insert was purified by gel extraction (Qiagen, Germany) and cloned into the 
EcoRI and HindIII sites of the eukaryotic expression vector pCMX-PL1 which was 
previously purified and prepared for ligation using T4-Ligase (NEB, Germany).67 After 
transformation in DH10ß cells (NEB, Germany) according to the manufacturer´ s 
instructions the plasmids were isolated using the MIDI Kit (Qiagen, Germany) and 
quantified by a gene quant II RNA/DNA Calculator (Pharmacia Biotech). The dnKCNN4 
constructs with amino acid replacements in the selectivity filter of the potassium channel 
were generated with the QuikChange Mutagenesis kit (Stratagene, Germany). The 
introduced amino acids are Leu253 (replacing Tyr; dnKCNN4 Y253L) and 
Ala252-Ala253-Ala254   (replacing Gly-Tyr-Gly; dnKCNN4 AAA). The sequences of the 
PCR-generated clones were confirmed by DNA sequencing. 
 
Transient Transfection  
For transient transfection, 2 x 105 cells per mL were seeded in 6-well plates (Corning 
Omnilab, Germany) and cultured in 2 mL of Dulbecco’s modified Eagle’s medium (PAA, 
Germany) with 10% fetal calf serum (Pan, Germany). Cells were transiently transfected 
with 1 µg of the respective plasmid using the LipofectaminPlus (Invitrogen, Germany) 
method according to the manufacturer’s instructions. The transfection efficiency was 
approximately 45%. To investigate the MIA protein secretion pathway Mel Im cells and 
Mel Ju cells were transfected with Sar1p (H79G) mutant (generous gift from Ben Distel, 
University of Amsterdam, NL) and the respective mock control plasmid pcDNA3. To 
demonstrate involvement of the KCNN4 channel in regulation of MIA protein secretion 
cells were transiently transfected with the expression plasmids KCNN4 (generous gift from 
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Albrecht Schwab, University of Münster, Germany), pCMX-PL1 hMIA, the dominant 
negative form dnKCNN4 AAA or dnKCNN4 Y253L and the respective mock control 
pCMX-PL1 and pcDNA3.67 48 h after transfection the cell culture supernatant was 
collected for quantification of secreted MIA protein by using an ELISA system (Roche 
Applied Science, Germany) as described above.  
For immunofluorescence staining experiments 105 Mel Im cells and Mel Ju cells, 
respectively, were grown on a four well chamber slide (Falcon, BD Bioscince, Germany). 
Transient transfection and co-transfection of these cells with MIA HisTag and Golgi-GFP 
(endomannosidase) plasmids (kindly provided by Christof Voelker, University of Bonn, 
Germany) and the respective mock control, respectively, were also performed using the 
LipofectaminPlus (Invitrogen, Germany) method according to the manufacturer’s 
instructions. First, cells were transfected with the Golgi-GFP plasmid and incubated for 
24 h before further treatment. During this time span the reorientation of the microtubule 
organizing center (MTOC), a comparatively slow process that can take several hours after 
migratory stimuli, is ensured. Afterwards, cells were co-transfected with the MIA HisTag 
plasmid and the respective mock control pCMX-PL1. After another 24 h cells were treated 
with various inhibitory compounds in different final concentrations, fixed and prepared for 
immunofluorescence microscopy.  
 
Immunofluorescence assays  
5 x 105 melanoma cells Mel Im and Mel Ju and human epithelial kidney cell line HEK293 
cells, respectively, were grown in a 4-well chamber slide (Falcon, BD Bioscience, 
Germany). After transient transfection and co-transfection with MIA HisTag and Golgi-
GFP plasmids and the respective mock control, cells were treated with BFA at final 
concentrations of 3.5 µM and 7 µM, AMP-PNP at final concentrations of 1 mM and 
2 mM, TRAM-34 at final concentrations of 20 µM and 40 µM and the respective DMSO 
control. After incubation for 1.5 h at 37°C and 8% CO2, cells were washed and fixed using 
4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 15 min. After 
permeabilization of cells, blocking of non-specific binding sites with blocking solution 
(1% BSA/PBS) for 1 h at 4°C was performed followed by incubation with primary 
antibody mouse anti-HisTag antibody (BD Bioscience, Pharmingen, Germany) at a 
concentration of 1 µg/mL at 4°C for 2 h. After rinsing with PBS for 5 times, cells were 
covered with a 1:30 dilution of the secondary antibody (FITC-conjugated polyclonal rabbit 
anti mouse immunoglobulin, DakoCytomation, USA) in PBS at 4°C for 1 h. For a better 
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illustration of the cell border cells were simultaneously stained for actin with phalloidin 
rhodamine dye (Biotium, USA) according to the manufactures instructions. Afterwards, 
cells were washed with PBS and coverslips were mounted on slides using Hard Set 
Mounting Medium with DAPI (Vectashield, H-1500, Linearis, Germany) and imaged 
using an Axio Imager Zeiss Z1 fluorescence microscope (Axiovision Rel. 4.6.3) equipped 
with an Axio Cam MR camera. Images were taken using 63x oil immersion lenses.  
 
Electrophysiological recordings  
Potassium currents were recorded at room temperature in the whole-cell configuration, 
using an EPC9 patch clamp amplifier (HEKA Elektronik, Germany) controlled with 
PatchMaster software (HEKA Elektronik). In all experiments, the holding potential was 
-80 mV. Series-resistance errors were compensated in the range of 70–90%. Patch pipettes 
were fabricated from Kimax-51 glass (Kimble Glass, USA) with resistance values in the 
range of 0.8-1.5 MΩ. Off-line analysis of data was performed using IgorPro 
(WaveMetrics, USA) and FitMaster (HEKA Elektronik). The internal solution contained 
(mM): KCl 130, MgCl2 2, EGTA 10, Hepes 10 and CaCl2 9.3 to yield 1 µM free Ca2+; pH 
was adjusted to 7.4 with KOH. The standard bath solution contained (mM): KCl 5, NaCl 
155, CaCl2 2 and Hepes 10; pH was adjusted to 7.4 with NaOH. Currents were elicited by 
500-ms voltage ramps, ranging from -100 mV to +50 mV. In block experiments with 
TRAM-34 the same ramp protocol was applied every 5 seconds. Mean current densities 
were determined between -40 mV and -25 mV.  Current recordings on transfected HEK293 
cells were performed 1-3 days after transfection. 
 
Statistical analysis  
In the bar graphs, results are expressed as mean ± s.d. (range) or percent. Comparison 
between groups was made using the Student's unpaired t-test. A p-value <0.05 was 
considered as statistically significant (ns: not significant, *: p<0.05, **: p<0.01, ***: 
p<0.001). All calculations were made using the GraphPad Prism Software (GraphPad 
Software, Inc., San Diego, USA). 
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Abstract 
MIA (melanoma inhibitory activity) protein, identified as a small 11 kDa protein highly 
expressed and secreted by malignant melanoma cells, plays an important functional role in 
melanoma development, progression and tumor cell invasion. Recent data describe a direct 
interaction of MIA protein with cell adhesion receptors integrin 41 and integrin 51 
and extracellular matrix molecules. By modulating integrin activity MIA protein mediates 
detachment of melanoma cells from surrounding structures resulting in enhanced invasive 
and migratory potential. However, until today a detailed understanding of the processes of 
MIA function is missing. 
In the present study, we show that after binding of MIA protein to integrin 51, MIA 
protein is internalized together with this cell adhesion receptor at the cell rear. This 
mechanism enables tumor cells to migrate in a defined direction as appropriate for invasion 
processes. Treatment of melanoma cells with PKC-inhibitors strongly reduced 
internalization of MIA protein. Endocytosis is followed by dissociation of MIA-integrin 
complexes. In acidic vesicles MIA protein is degraded while integrins are recycled. 
Treatment of melanoma cells with MIA inhibitory peptides almost completely blocked the 
MIA protein uptake into cells.  
Since MIA protein has a major contribution to the aggressive characteristics of malignant 
melanoma in particular to formation of metastasis, it is important to elucidate the MIA 
functional mechanism in tumor cells to find novel therapeutic strategies in the fight against 
skin cancer.  
 
The results of this chapter have been published: 
Schmidt J., Bosserhoff A.K.; Processing of MIA protein during cell migration. 
Int J Cancer 2009; 125(7):1587-94 
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3.1 Introduction 
Malignant melanoma is characterized by aggressive local growth and early formation of 
metastasis, and accounts for 75 percent of deaths associated with skin cancer. Previously, 
melanoma inhibitory activity (MIA) has been identified as an 11 kDa protein strongly 
expressed and secreted by malignant melanoma cells but not expressed in melanocytes.1 
Subsequent in vitro and in vivo experiments revealed that MIA protein plays an important 
functional role in melanoma development and cell invasion, hence MIA expression levels 
parallel closely the capability of melanoma cells to form metastases in syngeneic 
animals.2-4 Increased MIA serum concentrations serve as a reliable clinical tumor marker 
to detect and monitor metastatic diseases in patients with malignant melanomas.1, 5-6  
The three-dimensional structure of the protein was solved by multidimensional nuclear 
magnetic resonance (NMR) and X-ray crystallography techniques.7-10 Corresponding data 
indicate that MIA defines a novel type of secreted protein: the MIA protein family, 
consisting of MIA and the homologous proteins OTOR, MIA-2 and TANGO (MIA-3). The 
MIA protein family is the first family of secreted proteins comprising an SH3 domain like 
fold in solution.11 Furthermore, phage display experiments and NMR spectra revealed that 
MIA protein interacts with peptides matching to extracellular matrix proteins including 
human fibronectin type III repeats and laminin structures. In previous studies using far 
Western blotting and co-immunoprecipitation MIA protein was identified to bind to the 
cell surface proteins integrin 41 and integrin 51.12 Thus, MIA protein modulates 
integrin activity and thereby mediates detachment of cells from extracellular matrix 
proteins, resulting in enhanced invasive and migratory potential of melanoma cells. 
In cell migration processes integrins, mediating cell-cell and cell-extracellular matrix 
contacts, undergo endocytic-exocytic transport. Adhesion receptor recycling is described 
as a process where at the cell rear integrins are internalized and subsequently transported 
within recycling vesicles to the leading edge of the migrating cell. Here, they are 
re-exocytosed to build new adhesion contacts to extracellular matrix molecules.13-14 Now 
the question arises, how MIA protein contributes to migration and invasion after its 
secretion from tumor cells. This study elucidates the mechanism by which MIA protein 
promotes cell detachment and thus influences formation of cancer metastases. We found 
that extracellular MIA protein, directly binding to integrin 51, is internalized together 
with this cell adhesion receptor at the cell rear. This located uptake of MIA protein results 
in focal cell detachment at the rear cell pole and allows a directed migration. We also 
demonstrate that after MIA-integrin endocytosis, these receptor-MIA complexes dissociate 
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and MIA protein is degraded in acidic vesicles. Treatment of melanoma cells with MIA-
inhibitory peptides results in a dramatical decrease of MIA protein internalization in a dose 
dependant manner. Since MIA protein promotes invasive behavior of malignant melanoma 
cells, it is necessary to find a mechanistic explanation for observed MIA effects to develop 
a novel therapeutic strategy.  
 
3.2 Results 
3.2.1 Unidirectional internalization of MIA protein 
Integrin heterodimers are known to regulate cell adhesion and migration. The mechanism 
of integrin recycling by vesicular transport contributes to cell migration by internalizing 
integrins at the cell rear and thereby facilitates their detachment from surrounding 
structures.14 
In previous studies it has been shown that MIA protein directly interacts with integrin 41 
and integrin 51. This binding leads to cell detachment by decreasing interactions 
between melanoma cells and extracellular matrix molecules via inactivation of integrins. 
We, therefore, hypothesized that MIA protein regulates migratory behavior of melanoma 
cells by modulating integrin activity. This theory is supported by the fact that MIA 
expression levels directly correlate with the ability of melanoma cells to form skin cancer 
metastases.3-4 
As shown in Figure 1, Mel Im melanoma cells, seeded in medium confluence and 
incubated with Cy3-labeled MIA protein, show a strong Cy3-fluorescence intensity in 
intracellular vesicles asymmetrically distributed at one cell pole. About 40% to 50% of 
seeded Mel Im cells are migrating; nearly all of them present this characteristic 
unidirectional MIA-Cy3 staining pattern. Cells treated with Cy3-labeled BSA protein as a 
negative control under the same experimental conditions did not show any fluorescence 
signal, indicating that the labeled BSA protein is not endocytosed (Figure 1 D).  
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Figure 1: Internalization of MIA protein at one cell pole 
Mel Im cells were treated with Cy3-labeled MIA protein and, as a negative control, with Cy3-labled BSA 
protein. (A) Migrating cells internalize MIA protein and show a strong Cy3-fluorescence intensity 
asymmetrically distributed at one cell pole as indicated by the white arrows. (B) DAPI (C) Merge (D) BSA 
Cy3 negative control 
 
The same characteristic MIA protein uptake was also found in all other melanoma cell 
lines tested: Mel Ju, SK Mel 28 and A375 (Supplementary Figure S2). 
Since MIA protein specifically interferes with attachment of melanoma cells we recently 
performed a phage display screening experiment to identify potential MIA-inhibitory 
peptides. These peptides were investigated in attachment analysis in a Boyden Chamber 
model on their ability to affect MIA function.2 AR54, one of these peptides deduced from 
the FN14 structure, was able to almost completely inhibit MIA function at concentrations 
of 1 µM without affecting integrin function (Supplementary Figure S1B).9  
After treatment of Mel Im cells with AR54 the endocytosis of Cy3-labeled MIA protein 
was reduced in a dose dependent manner. AR54 at concentrations of 0.3 µM and 0.5 µM 
moderately decreases MIA protein endocytosis whereas a concentration of 2 µM almost 
completely inhibits MIA uptake as shown in Figure 2.  
 
B C D A 
AR54  (-) AR54  0.3 µM AR54  0.5 µM AR54  2.0 µM 
 
Figure 2: Dose dependent inhibition of MIA protein internalization by peptide AR54  
Mel Im cells simultaneously were treated with Cy3-labeled MIA protein (A) and AR54, a MIA protein 
binding peptide, which was able to inhibit MIA function. AR54 was added in different concentrations. Final 
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concentrations of 0.3 µM (B) and 0.5 µM (C) moderately decrease MIA protein endocytosis whereas 
concentrations of 2 µM (D) almost completely inhibit MIA protein uptake. 
 
For all other melanoma cell lines tested we observed comparable results (Supplementary 
Figure S3). 
 
3.2.2 Internalization of MIA-integrin complexes at the rear of migrating cells 
To further elucidate the MIA protein function in migratory behavior of melanoma cells, we 
determined the direction of cell migration. Illustrated in Figure 3 are two independent 
examples (I and II) where the observed MIA fluorescence staining pattern argues for a 
coordinated MIA protein uptake located at one cell pole (A). As generally accepted, 
directed migration begins with cell polarization and it has been shown in previous studies 
that the microtubule organizing center (MTOC) and the Golgi apparatus are reoriented 
toward the leading edge of cells in wound-healing migration assays.15-17 For the 
determination of the migration direction of Mel Im cells, cells were incubated with Cy3-
labeled MIA protein (A) and afterwards stained with a Golgi marker (mouse anti-Golgi 
protein [58K 9] antibody) (B). Fluorescence analysis shown in Figure 3 revealed the 
uptake of MIA protein containing vesicles at the cell rear, confirming our hypothesis that 
MIA protein is strongly involved in detachment processes of migrating cells. This 
mechanism enables tumor cells to migrate in a defined direction. Non-polarized cells and 
thus non-migrating cells, perceptible by the homogeneous green staining (II B), do not 
show the characteristically distributed Cy3 fluorescence (II A). Using the other melanoma 
cell lines, in migrating cells the same fluorescence staining pattern appears. A375 cells, 
similar to Mel Im cells, show a strong migratory ability compared to the other cell lines 
Mel Ju and SK Mel 28 (Supplementary Figure S4).   
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Figure 3: MIA protein is internalized at the rear of migrating cells 
For determination of the direction of migration, Cy3-labeled MIA treated Mel Im cells were stained with a 
Golgi marker mouse anti-Golgi protein [58K 9] antibody. The uptake of Cy3-labeled MIA containing 
vesicles takes place at the rear part of the cell (A) since the location of the MTOC-Golgi apparatus is toward 
the leading edge of migrating cells (B). Non-polarized cells and thus non-migrating cells, perceptible by the 
homogeneous green staining, do not show the characteristic MIA fluorescence located at the cell rear. (C) 
DAPI. (D) Merge.  I and II are representative examples of two independent experiments. 
 
The observation that the MIA vesicular staining appears at the cell rear and the fact that 
MIA protein specifically binds to integrin structures 41 and 51 prompted us to 
investigate whether MIA protein is internalized together with integrins after binding. 
Therefore, Mel Im cells were treated with Cy3-labeled MIA protein and stained with anti 
integrin 1 [CD29] antibody. As illustrated in Figure 4, fluorescence-labeled integrins are 
distributed all over the cell, whereas in close proximity to the cell membrane integrins 
appear to accumulate (B). Interestingly, at early stages of the endocytosis process close to 
the cell membrane, we observed that these integrins are co-localized with Cy3-labeled 
MIA protein, in particular at the cell rear (C). After staining with an 
anti-integrin 5 antibody we observed a similar staining pattern (data not shown). The 
same results were found for the other melanoma cell lines investigated (Supplementary 
Figure S5). These findings are also supported by data presented in previous studies. Based 
on far Western blotting and co-immunoprecipitation assays we found a direct interaction of 
MIA protein with integrin 41 and integrin 51.12 Together, these results suggest MIA 
protein to be internalized into the cell together with integrins 51 after binding to these 
cell adhesion molecules and thereby blocking formation of extracellular matrix contacts.  
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Figure 4: Internalization of MIA-integrin complexes 
Mel Im cells were treated with Cy3-labeled MIA protein. After fixation cells were stained with anti integrin 
1 [CD29] antibody. (A) Cy3-labeled MIA protein is mainly located at one cell pole (B) 
Immunofluorescence-stained integrins are distributed all over the cell and accumulate at or close to the cell 
membrane. (C) Merge. As indicated in the image section by the white arrows, in regions under the 
cytoplasmic membrane, we observed that integrin 1 co-localizes with Cy3-labeled MIA protein, here 
depicted in red. This phenomenon was observed especially at the cell rear.  
 
Nowadays, it is known that integrins are either internalized by clathrin-dependent 
mechanisms or by non clathrin-dependent mechanisms.18-19 In terms of the latter, integrins 
can enter caveolae followed by an internalization route that is regulated by protein kinase 
Cand dynamin.20  Since we found that MIA protein uptake into cells that were treated 
with GÖ6976 (C), blocking PKCand , or BIMI (B), inhibiting PKC,  and , was 
dramatically decreased (Figure 5), our theory of integrin mediated MIA protein uptake was 
further supported. 
 
A B
C D
Image section Merge 
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Figure 5: Inhibition of endocytosis of MIA-integrin complexes by PKC-inhibitors 
Mel Im cells were incubated simultaneously with Cy3-labeled MIA and PKC inhibitors. The DMSO control 
shows the unidirectional Cy3-labeled MIA protein staining at the cell rear (A). Treatment with PKCand 
, inhibitor BIM I (30 µM) (B) and PKC and inhibitor GÖ6976 (30 µM) (C), respectively, leads to a 
dramatical decrease in endocytosis of Cy3-labeled MIA protein. 
  
3.2.3 Intracellular dissociation of MIA-integrin complexes and degradation of MIA 
protein 
In the cytoplasm close to the nucleus, Cy3-labeled MIA protein shows no co-localization 
with integrins (Figure 4 C). Thus, we concluded that MIA-integrin complexes were 
dissociated after endocytosis and that the two proteins now were transported in different 
ways. As with other cycling receptors, integrin heterodimers internalize to early 
endosomes from which they can be either returned directly to the plasma membrane or 
further trafficked to the perinuclear recycling compartment before recycling through 
Rab11- and/or Arf6-dependent mechanisms.14, 21-23 In Figure 6 two independent examples 
(I and II) for Mel Im cells treated with Cy3-labeled MIA protein and stained with anti-
Rab11 antibody are illustrated. The MIA protein internalization takes place at the rear cell 
pole (A) whereas the Rab11 staining, here depicted in red, is homogeneously distributed all 
over the cell (B). Since Cy3-labeled MIA protein and integrin transporter-protein Rab11 do 
not co-localize (D), our model of intracellular dissociation of endocytosed MIA-integrin 
complexes further was confirmed. Under the same experimental conditions all other 
melanoma cell lines show comparable results: Cy3-labeled MIA protein does not co-
localize with integrin transporter-protein Rab11 (Supplementary Figure S6).  
 
DMSO BIM I 30 µM GÖ6976 30 µM 
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Figure 6: Dissociation of endocytosed MIA-integrin complexes 
Mel Im cells were treated with Cy3-labeled MIA protein (A). After fixation, cells were incubated with 
anti-Rab11 antibody (B). After endocytosis of Cy3-labeled MIA protein it was cleaved from integrins. Thus 
the integrin transporter-protein Rab11 depicted in red, mediating integrin recycling, does not co-localize with 
MIA protein. (C) DAPI. (D) Merge. I and II are examples of two independent experiments. 
 
To elucidate the fate of internalized MIA protein, we treated cells with Lysotracker red 
DND99, a chromophore which specifically stains acidic vesicles red in the cytoplasm of 
cells (Figure 7 B). Lysosomes are organelles containing digestive enzymes catalyzing 
hydrolysis of macromolecules like proteins, polysaccharides, lipids and nucleic acids. The 
membrane surrounding lysosomes allows the enzymes to work at a pH value of 4 to 5, 
where these enzymes achieve a high activity. Mel Im melanoma cells were incubated with 
unlabeled MIA protein. Afterwards, MIA staining was performed using a rabbit anti-MIA 
antibody. As shown in two independent examples I and II in Figure 7 A, MIA protein 
distribution depicted in green is similar to that of Cy3-labeled MIA protein shown in 
previous figures: there is a targeted uptake of MIA protein detectable at the cell rear of 
migrating cells. As indicated by the white arrows, exactly in regions comprising assemblies 
of acidic compartments colored in red, there was no MIA-staining detectable, pointing to 
degradation of MIA protein inside lysosomes. This phenomenon of disappearance of MIA 
signals strongly contributes to our model of dissociation of MIA protein from integrins 
after internalization.  
 
MIA Cy3 Rab11 DAPI Merge 
I 
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Figure 7: Degradation of MIA protein after internalization  
Mel Im cells were treated with unlabeled MIA protein and Lysotracker red DND99, a chromophore which 
specifically stains acidic vesicles red in the cytoplasm of cells. After fixation, MIA protein staining was 
performed using a rabbit anti-MIA antibody. (A) MIA protein distribution depicted in green is similar to that 
of Cy3-labeled MIA protein: there is a targeted MIA protein uptake detectable at the cell rear of migrating 
cells. As indicated by the white arrows, exactly in regions comprising assemblies of acidic compartments 
colored in red (B), there was no MIA-staining detectable. (C) DAPI. (D) Merge. I and II represent two 
independent examples. 
 
To further confirm our hypothesis of MIA protein degradation, cells were also treated with 
LysoTracker green DND26 together with Cy3-labeled MIA protein. As displayed in 
Figure 8 C, MIA protein co-localizes with acidic cell compartments in close proximity to 
the nucleus. Unlike detection of MIA protein using an anti-MIA antibody shown in 
Figure 7, this continuous Cy3-fluorescence signal is still detectable inside cytoplasmic 
acidic vesicles after digestion of the protein at a pH range of pH 4 to 5. In summary, our 
results demonstrate that MIA protein is internalized into the cell together with integrins 
and that MIA-integrin binding is dissociated. In the next step, MIA protein is digested in 
acidic vesicles while integrins are recycled. 
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Figure 8: Degradation of MIA protein in acidic lysosomes  
Mel Im cells simultaneously were treated with Cy3-labeled MIA protein (A) and LysoTracker green DND26 
staining acidic lysosomes (B). As illustrated in the merge picture (C), MIA protein co-localizes with acidic 
cell compartments in the cytoplasm at the centre of the cell close to the nucleus. Co-localization is depicted 
in red and in the image section it is also indicated by white arrows.  
 
3.3 Discussion 
In this study, we analyzed the mechanism by which MIA protein, expressed and secreted 
by malignant melanoma cells, contributes to alteration of migratory and invasive behavior 
of these tumor cells. In previous investigations it was shown that MIA protein binds to 
extracellular matrix molecules including fibronectin, laminin and tenascin.2 MIA protein 
was also described to directly interact with the cell adhesion molecules integrin 41 and 
integrin 51.12 As a result, matrix structures are masked by MIA protein and moreover, 
neoplastic melanocytes enhance their metastatic capability by specifically changing their 
attachment to surrounding extracellular matrix molecules and basement membranes. 
Experimental data described in this study demonstrate that secreted MIA protein is 
internalized together with integrin 51 after directly binding to this adhesion receptor at 
the cell surface. We also demonstrate that endocytosis is followed by dissociation of MIA-
integrin complexes. Afterwards, MIA protein is degraded in acidic vesicles. 
A similar endocytosis mechanism was also described for vitronectin, a plasma protein 
which was also found in the extracellular matrix. Many functions have been characterized 
for vitronectin, including regulation of the activity of both thrombin and plasminogen 
activator, as well as modulating the membrane attack complex of complement. Vitronectin 
comprises an Arg-Gly-Asp (RGD) sequence that can bind to either the v3 or the v5 
integrin receptor.24-26 Similar to MIA protein, vitronectin also mediates cell adhesion by 
this interaction. As a special feature for internalization of vitronectin together with the cell 
A B C
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adhesion receptor, the interaction of both the v5 integrin and a species of heparan sulfate 
proteoglycan are required. Binding to the extracellular matrix is a prerequisite for 
endocytosis of vitronectin deduced by the observation that multimeric vitronectin does not 
appear to be degraded from the fluid phase. Identical to what we observed for MIA protein, 
receptor-mediated endocytosis is followed by subsequent degradation of vitronectin in 
lysosomes. Further, it was demonstrated that effectors of protein kinase C, involved in 
signaling pathways between transmembrane signaling receptors, modulate vitronectin 
degradation by regulating the internalization.24 The inhibition of receptor mediated 
endocytosis of MIA protein in cells treated with protein kinase C inhibitors BIMI and 
GÖ6976 contributes to our hypothesis that MIA protein internalization may be regulated 
by a similar mechanism. Unlike vitronectin, MIA protein is bound to the cell surface 
receptor integrin 51 before internalization. In previous studies, it was reported that 
remodeling of matrix structures occurs via internalization of extracellular matrix proteins 
and degradation in lysosomes.27-30 It was shown that - identical to MIA protein - turnover 
of extracellular matrix protein fibronectin is processed via integrin 51 internalization. 
This endocytosis mechanism is constitutively regulated by caveolin-1 and can occur in 
presence or absence of fibronectin and fibronectin matrix.31 Not all fibronectin binding 
integrins can promote fibronectin endocytosis. Of the integrins tested, only 51 integrin 
was shown to participate in fibronectin endocytosis. Identical to our results for MIA 
protein it was also demonstrated that matrix turnover of fibronectin is followed by 
lysosomal degradation.32  
Further, the prevention of MIA protein internalization after treatment of cells with peptides 
deduced from extracellular matrix proteins and integrin structures is consistent with our 
proposed mechanism. Before initial binding to integrin receptors, MIA protein was 
captured by these peptides. Next to their canonical role in physical adhesion of cells, 
interactions between cell surface molecules and matrix components provide pivotal 
contributions to a broad range of cellular processes in melanocytic cells. Thus, active 
detachment of melanoma cells induced by MIA protein may also be implicated in 
regulation of migration, apoptosis, secretion of proteases or matrix proteins, and cell 
growth.33-38 It is known that such interactions between melanocytic cells and extracellular 
matrix involve foremost binding of integrins to specific epitopes within fibronectin and 
depend, to a significant extent, on activation of integrin 41 and integrin 51.37 
Detachment from surrounding matrix structures is a basic requirement for melanoma cells 
to migrate, invade and finally metastasize in a systemic disease. To impair formation of 
49 
3   Processing of MIA Protein during Melanoma Cell Migration 
 
 
50 
metastases and control malignant melanoma metastases at the invasive state it is necessary 
to anticipate MIA binding to integrins and extracellular matrix molecules. Previously 
published data provide first evidence for a reduction of tumor size after application of two 
fibronectin-deduced peptides in a mouse melanoma model.2  
In summary, our results demonstrate that MIA protein, binding to integrins and thus 
promoting detachment of cells from extracellular matrix structures, is internalized into the 
cell together with these cell adhesion receptors at the cell rear. MIA-integrin binding 
dissociates and in the next step, MIA protein is digested in acidic vesicles while integrins 
are recycled. Prevention of MIA protein internalization by capturing the protein by 
inhibitors in vivo may provide a novel therapeutic strategy for therapy of patients suffering 
from malignant melanoma. 
 
3.4 Materials and Methods 
Cell lines and cell culture conditions 
The melanoma cell line Mel Im, established from a human metastatic bioptic sample 
(generous gift from Dr. Johnson, University of Munich, Germany) was used in all 
experiments. Additionally, main experiments were also conducted using human cell lines 
Mel Ju, SK Mel 28 and A375, which were all derived from metastasis of malignant 
melanoma. Cells were maintained in DMEM (PAA Laboratories GmbH, Austria) 
supplemented with penicillin (400 U/mL), streptomycin (50 µg/mL), l-glutamine 
(300 µg/mL) and 10% fetal calf serum (Pan Biotech GmbH, Germany) and split in 
1:5 ratio every 3 days. 
 
Protein labeling 
For the conjugation of the orange fluorescing cyanine dye Cy3, 0.11 mg MIA protein or 
0.4 mg BSA, respectively, was dissolved in 1 mL sodium carbonate-sodium bicarbonate 
buffer (pH 9.3), added to the dye vial (CyTM3 Mono-Reactive Dye Pack, Amersham GE 
Healthcare, UK) and mixed thoroughly. The reaction was incubated at room temperature 
for 50 min before separation of protein from free dye by using a SephadexTM 
G-25 M PD-10 Desalting column (Amersham Pharmacia Biotech, Sweden). During elution 
two pink bands occurred; the faster moving band represents Cy3-labeled MIA protein and 
Cy3-labeled BSA, respectively. The procedure was designed to label protein to a final 
molar dye/protein ratio between 4 and 12.  
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The fluorescent Cy3 label does not affect binding properties of MIA protein, as deduced 
from Boyden Chamber invasion experiments, where Mel Im cells were treated with Cy3-
labeled MIA protein and, in comparison, with unlabeled MIA protein (Supplementary 
Figure S1A).  
 
Immunofluorescence assays 
5 x 105 melanoma cells, Mel Im, Mel Ju, SK Mel28 and A375, respectively, were grown in 
a 4-well chamber slide in 500 µl DMEM and incubated with 35 µl 4.5 µM Cy3-labeled 
MIA protein or BSA, respectively, for 90 min at 37°C and 5% CO2. Afterwards, cells were 
washed and fixed using 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) 
for 15 min and permeabilized.39 After rinsing with PBS for 5 times, coverslips were 
mounted on slides using Hard Set Mounting Medium with DAPI (Vectashield, H-1500) 
and imaged using an Axio Imager Zeiss Z1 fluorescence microscope (Axiovision Rel. 
4.6.3) equipped with an Axio Cam MR camera. Images were taken using 40x or 63x oil 
immersion lenses. For a better illustration in all pictures Cy3 staining is depicted in yellow. 
Conspicuous extracellularly located yellow dots perceptible in images comprising MIA 
Cy3 staining are dye-artifacts. 
For Golgi marker experiments cells were seeded and incubated for 24 h before further 
treatment. During this time span the reorientation of the microtubule organizing center 
(MTOC), a comparatively slow process that can take several hours after migratory stimuli, 
is ensured. After fixation of cells with 4% paraformaldehyde in 0.1 M PBS, permeabilizing 
and blocking of non-specific binding sites with blocking solution (1% BSA/PBS) for 1 h at 
4°C and rinsing was performed. Cells were incubated with primary antibody mouse anti-
Golgi protein [58K 9] antibody (Abcam, UK) in concentrations of 1 µg/mL at 4°C for 2 h. 
The amount of migrating cells was determined by counting 50 cells three times. Cells 
which show the characteristic MTOC staining pattern at the cell front were evaluated as 
“migrating”, whereas non-polarized cells that show homogenously distributed staining 
were counted as “non-migrating”. 
To illustrate co-localization of MIA protein with integrin 51, cells were incubated with a 
1:60 dilution of mouse anti human integrin 1 [CD29] antibody (Chemicon International, 
USA) or a 1:40 dilution of mouse anti human integrin 5 antibody (Chemicon 
Internatonal, USA), respectively, at 4°C for 2 h after Cy3-labeled MIA protein treatment, 
fixation with 4% paraformaldehyde in PBS, permeabilization and blocking of non-specific 
binding with 1% BSA / PBS. To exclude non-specific binding of target primary antibody 
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due to Fc-binding or other protein-protein interactions, we also used a mouse IgG isotype 
control antibody (Chemicon) (data not shown).  
To generate MIA / Rab11 co-staining, cells were treated with Cy3-labeled MIA protein, 
fixed with 4% paraformaldehyde in PBS, permeabilized and non-specific binding sites 
were blocked using 1% BSA / PBS. Afterwards, cells were incubated with a 1:50 dilution 
of mouse anti Rab 11 antibody (BD Bioscience Pharmingen, USA) at 4°C for 2 h. After 
rinsing with PBS for 5 times, cells were covered with a 1:30 dilution of the secondary 
antibody (FITC-conjugated polyclonal rabbit anti mouse immunoglobulin, 
DakoCytomation, USA) in PBS at 4°C for 1 h. Afterwards, cells were washed with PBS 
and mounted with Hard Set Mounting Medium with DAPI (Vectashield, H-1500, USA) or 
Hard Set Mounting Medium without DAPI (Vectashield, H-1400, USA), respectively. 
To selectively stain acidic lysosomes, Mel Im cells, grown on a 4-well chamber slide, were 
incubated with LysoTracker red DND99 (Molecular Probes, Invitrogen, USA) in a 
concentration of 60 nM for 90 min at 37°C, 5% CO2. Afterwards, cells were washed, fixed 
using 4% paraformaldehyde in 0.1 M PBS for 15 min and permeabilized. After rinsing 
with PBS for 5 times, cells were covered with blocking solution (1% BSA / PBS) for 1 h at 
4°C followed by incubation with an 1:20 dilution of primary antibody rabbit anti MIA 
antibody  (Biogenes, Berlin, Germany) for 2 h at 4°C. After washing with PBS, cells were 
incubated with a 1:30 dilution of the secondary antibody (FITC conjugated swine anti 
rabbit immunoglobulin, DakoCytomation). In case of simultaneously staining acidic 
lysosomes, LysoTracker green DND26 (Molecular Probes, Invitrogen, USA) in a 
concentration of 600 nM was incubated together with Cy3-labeled MIA protein on Mel Im 
cells for 90 min at 37°C and 5% CO2. Without fixation, cells were washed with PBS and 
mounted using Hard Set Mounting Medium without DAPI (Vectashield, H-1400, USA). 
 
MIA inhibitory peptide and PKC inhibitors 
For inhibition of MIA protein uptake, Mel Im, Mel Ju, SK Mel28 and A375 cells, 
respectively, together with Cy3-labeled MIA protein and the respective inhibitor were 
incubated for 90 min at 37°C and 5% CO2. Inhibitors were used in several final 
concentrations. AR54 (sequence: NSLLVSFQPPRAR), a MIA binding peptide deduced 
from peptide FN14, which was previously identified in a phage display experiment, was 
synthesized on solid-phase using HOBt / TBTU / DIEA and Rink Amide MBHA resin and 
was used at concentrations of 0.3 µM, 0.5 µM, and 2 µM.9 Its ability to block MIA 
function was tested using a Boyden Chamber invasion assay.2 AR54 at a final 
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concentration of 1 µM was able to almost completely inhibit MIA function without 
affecting integrin activity, indicating that specific binding of AR54 to MIA protein 
anticipates MIA interaction to extracellular matrix molecules and integrins (Supplementary 
Figure S1B). 
 As a negative control cells were also treated with scrambled peptide AR5 (sequence: 
Gly-Gly-Ser-Gly-NH2) in concentrations of 1 µM and 3 µM. In all cases Cy3-labeled MIA 
protein uptake was not affected by AR5 (data not shown). 
Both PKC inhibitors 3-(N-[Dimethylamino]propyl-3-indolyl)-4-(3-indolyl)maleimide3-
[1-[3-(Dimethylamino)propyl]1H-indol-3-yl]-4-(1Hindol-3-yl)1H-pyrrole-2,5dione 
Bisindolyl-maleimide I (BIM I) and 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-
oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole (GÖ6976) were used in a final concentration 
of 30 µM. As a control, cells were treated with DMSO. 
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3.7 Supplementary Information 
 
 
Figure S1: Invasion of Mel Im cells (indicated in %, control set as 100%) was measured in Boyden 
Chambers. Polycarbonate filters with 8 µm pore size were coated with matrigel. Fibroblast-conditioned 
medium was placed as a chemoattractant into the lower compartment. After incubation at 37°C for 4 hours, 
cells adhering to the lower filter surface were fixed, stained and counted. All data were observed in at least 
three independent experiments. (A) Mel Im cells were treated with Cy3-labeled MIA protein and unlabeled 
MIA protein (50 ng/ml), respectively. The fluorescent Cy3 label does not affect binding properties of MIA 
protein. (B) Mel Im cells were treated with MIA protein, MIA inhibitory peptide AR54 together with MIA 
protein and AR54 alone. AR54 at a final concentration of 1 µM was able to almost completely inhibit MIA 
function without affecting integrin activity, indicating that specific binding of AR54 to MIA protein 
anticipates MIA interaction to extracellular matrix molecules and integrins.  
 
 
 
 
 
Figure S2: The melanoma cell lines Mel Ju, SK Mel 28 and A375 were treated with Cy3-labeled MIA 
protein and as a negative control with Cy3-labeled BSA. (A) Migrating cells internalize MIA protein and 
show a strong Cy3-fluorescence intensity asymmetrically distributed at one cell pole. (B) DAPI (C) Merge 
(D) BSA Cy3 negative control. 
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Figure S3: Mel Ju, SK Mel 28 and A375 cells simultaneously were treated with Cy3-labeled MIA protein 
(A) and AR54, a MIA protein binding peptide, which was able to inhibit MIA function. AR54 was added in 
different concentrations. Final concentrations of 0.3 µM (B) and 0.5 µM (C) moderately decrease MIA 
protein endocytosis whereas concentrations of 2 µM (D) almost completely inhibit MIA protein uptake. 
 
 
 
 
 
 
 
 
 
Figure S4: For determination of the direction of migration, Cy3-labeled MIA treated Mel Ju, SK Mel 28 and 
A375 cells, respectively, were stained with a Golgi marker mouse anti-Golgi protein [58K 9] antibody. The 
uptake of Cy3-labeled MIA containing vesicles takes place at the rear part of the cell (A) since the location of 
the MTOC-Golgi apparatus is toward the leading edge of migrating cells (B). (C) DAPI. (D) Merge.  
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Figure S5: Melanoma cell lines Mel Ju, SK Mel 28 and A375 were treated with Cy3-labeled MIA protein. 
After fixation cells were stained with anti integrin 1 [CD29] antibody. (A) Cy3-labeled MIA protein is 
mainly located at one cell pole (B) Immunofluorescence-labeled integrins are distributed all over the cell and 
accumulate at or close to the cell membrane. (C) Merge. As indicated by the white arrows, in regions under 
the cytoplasmic membrane, we observed that integrin 1 co-localizes with Cy3-labeled MIA protein. This 
phenomenon was observed especially at the cell rear.  
 
 
 
 
 
Figure S6: Mel Ju, Sk Mel 28 and A375 cells, respectively, were treated with Cy3-labeled MIA protein (A). 
After fixation, cells were incubated with anti-Rab11 antibody (B). After endocytosis of Cy3-labeled MIA 
protein was cleaved from integrins. The integrin transporter-protein Rab11, mediating integrin recycling, is 
here depicted in red. (C) DAPI. (D) Merge. MIA protein, shown in yellow, and Rab11, depicted in red, do 
not co-localize.  
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4 Heterogeneous Transition Metal-based Fluorescence Polarization 
(HTFP) Assay for Probing Protein Interactions 
 
Abstract 
Analyses of protein interactions are fundamental for the investigation of molecular 
mechanisms responsible for cellular processes and diseases as well as for drug discovery in 
the pharmaceutical industry. The present study details the development of a fluorescence 
polarization (FP) assay using the example of Melanoma Inhibitory Activity (MIA)-binding 
compounds and studies of the binding properties of this protein. Already existing FP assays 
can, dependent on the lifetime of the fluorescent label, only determine interactions with 
either high or low molecular weight interaction partners. Our new concept eliminates this 
limitation by immobilizing a known binding partner of MIA protein to a well plate and by 
labeling the target protein using luminescent transition metal labels such as Ru(bpy)3 for 
binding studies with both high and low molecular weight interaction partners. Due to the 
use of a functionalized surface, we termed our concept Heterogeneous Transition metal 
based FP assay (HTFP). The independency of the assay from molecular weight of potential 
binding partners allows investigations on subjects as diverse as multimerization, 
interactions with pharmacophores or determination of binding affinities.  
 
The results of this chapter have been published: 
Riechers, A., Schmidt, J., König, B., Bosserhoff, A. K.; Heterogeneous Transition Metal-
based Fluorescence Polarization (HTFP) Assay for Probing Protein Interactions. 
Biotechniques 2009; 47, 837-844. 
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4.1 Introduction 
Protein interactions play a fundamental role in many biochemical processes like signal 
transduction, immune reaction, cell cycle control, differentiation and protein folding. They 
are also responsible for a number of diseases including cancer due to loss of protein 
function as a consequence of mutations. The search for potent and selective inhibitors for 
specific proteins is essential in pharmaceutical drug design and various techniques have 
been established for probing protein interactions. However, the applicability of the 
techniques is often restricted by the molecular weight of the binding partners. We describe 
here a screening assay based on fluorescence polarization measurements enabling high 
throughput screening and addressing this limitation by using the example of MIA-
inhibitory compounds. MIA protein has previously been identified as an 11 kDa molecule 
physiologically produced by cartilage, strongly expressed and secreted by malignant 
melanoma cells but not expressed in melanocytes.1-2 Since MIA protein expression levels 
in vivo directly correlate with progressive malignancy of melanocytic tumors it serves as a 
reliable clinical tumor marker to detect and monitor metastatic diseases.1, 3-4 Recent data 
describe a direct interaction of MIA protein with cell adhesion receptors integrin 41 and 
integrin 51 and extra cellular matrix molecules including fibronectin.5-6 By modulating 
integrin activity and masking matrix structures MIA protein mediates detachment of 
melanoma cells resulting in enhanced invasive and migratory potential that finally strongly 
contributes to the formation of metastasis.7 In previous studies, the MIA binding peptide 
FN14, matching a fibronectin domain, was identified in a phage display experiment.7-8 
AR54, a MIA binding peptide deduced from peptide FN14 was able to functionally inhibit 
MIA protein in vitro. Using this peptide we aimed to establish an assay which allows 
detection of potential MIA-inhibitory compounds.  
To investigate interactions of MIA protein, commonly used methods like fluorescence 
emission titration and FRET-based experiments were found to be inappropriate due to 
inherent tendency of MIA protein to form aggregates.8 Since Dynamic Light Scattering 
(DLS), NMR and isothermal calorimetry (ITC) were not sensitive enough to detect binding 
events at physiologically relevant concentrations, we decided to employ fluorescence 
polarization for elucidating the interaction of MIA protein with AR54. However, 
traditional FP assays are limited by the molecular weight of the interaction partner. For the 
evaluation of binding of low molecular weight compounds to proteins, assays are 
performed entirely in solution and are thus limited to the use of organic fluorophores due 
to the short fluorescence lifetime required. Typically, the displacement of an already 
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known and labeled inhibitory compound from the target protein by a low molecular weight 
drug candidate is determined in these FP assays. Although luminescent transition metal 
complexes have been used in FP immunoassays 9-21 this assay concept in solution is not 
feasible for binding investigations of low molecular weight compounds, for example in 
drug candidate screening due to the dependence of fluorescence polarization on molecular 
weight and fluorescence lifetime. Luminescent transition metal complexes have a number 
of advantages compared to organic fluorophores such as a large Stokes shift, high 
photostability and the option to be used in time-gated measurements. These time-gated 
measurements offer the possibility of multiple labeling using transition metals with 
different lifetimes despite possible spectral overlap and the elimination of autofluorescence 
of biological material. By using a well plate functionalized with a MIA protein binding 
compound, we created a binding partner of significantly higher molecular weight than any 
peptide or protein. As described here, we have developed a fluorescence polarization assay 
capable of handling both high and low molecular weight interaction partners and termed 
our experimental setup Heterogeneous Transition metal based Fluorescence Polarization 
(HTFP) assay. 
 
4.2 Results 
In malignant melanoma, MIA protein facilitates cell detachment by mediating integrin 
activity and further by masking binding sites for cell adhesion molecules at extracellular 
matrix structures. To prevent formation of metastasis it is desirable to find substances that 
specifically bind to MIA protein and thereby functionally reduce MIA-induced effects. 
Here, MIA and known binding partners were used to develop an assay format capable of 
high throughput analysis based on fluorescence polarization measurements to identify and 
characterize protein interactions. The use of a multi-well plate makes it possible to assay 
more samples in significantly less time using few reagents.  
 
4.2.1 Heterogeneous Transition metal based Fluorescence Polarization (HTFP) assay 
development 
Peptide AR54, deduced from the peptide FN14, which was previously identified in a phage 
display experiment,7-8 was tested for its ability to functionally inhibit MIA protein in vitro 
using a Boyden Chamber invasion assay. The peptide was able to almost completely 
inhibit MIA protein function by preventing interactions of MIA protein with extracellular 
matrix molecules and integrins without affecting cell migration itself.22 This prompted us 
62 
4   HTFP Assay for Probing Protein Interactions 
 
63 
to investigate this interaction of the inhibitory peptide with MIA in fluorescence emission 
titration experiments, a method that is generally used to obtain information about 
stoichiometry and binding constants. While a FRET experiment with an 
N-methylanthraniloyl labeled AR54 derivative failed due to spectral overlap, FP 
experiments with a carboxyfluorescein labeled derivative were compromised by 
nonspecific interactions of MIA protein and the respective control protein with the 
fluorophore. We, therefore, reevaluated the choice of our assay format and decided to 
establish a new fluorescence polarization based assay. 
By labeling the protein rather than the inhibitor AR54, we envisioned that a large change in 
molecular weight should be observable if the labeled protein of interest was bound by an 
inhibitory compound immobilized to a well plate (Figure 1). As a label, we chose the 
luminescent Ru(bpy)3 complex due to its sufficiently long lifetime. The FP signal should 
decrease after competitive displacement of labeled MIA protein from immobilized AR54 
by an inhibitory compound.  
 
 
 
Figure 1: Concept of the FP assay using a luminescent transition metal complex as label  
Binding of Ru(bpy)3-labeled MIA protein to the immobilized inhibitory peptide AR54 leads to a large 
change in molecular weight resulting in a dramatic increase of the fluorescence polarization signal (left). 
After competitive displacement of labeled MIA protein from immobilized AR54 by an inhibitory compound 
(right) the FP signal decreases. The HTFP assay enables the performance of a high throughput screening of 
large substance libraries in search for a potent MIA protein inhibitor. 
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4.2.2 Functional activity of Ru(bpy)3-labeled MIA protein  
To ensure that the luminescent Ru(bpy)3-label does not affect binding properties of MIA 
protein we performed Boyden Chamber invasion experiments, where Mel Im cells were 
treated with Ru(bpy)3-labeled MIA protein and, in comparison, with unlabeled MIA 
protein. Non-modified MIA protein reduces cell invasion by about 40% to 50% in this in 
vitro model since MIA protein specifically interferes with attachment of melanoma cells to 
matrigel.7 Both MIA proteins, the unlabeled and the Ru(bpy)3 labeled one behave 
identically revealing that Ru(bpy)3-labeled MIA is functionally active (data not shown).  
 
4.2.3 Heterogeneous Transition metal based Fluorescence Polarization (HTFP) assay 
results 
 
4.2.3.1 Binding of MIA-Ru(bpy)3 to AR54, 30 kDa and 70 kDa fibronectin fragments 
First, we measured the FP signal of MIA-Ru(bpy)3 in a well coated with AR54-Biotin 
compared to an uncoated well. The significant increase in FP in the well coated with 
AR54-Biotin was attributed to the severely restricted rotational mobility of MIA-Ru(bpy)3 
bound to the immobilized AR54-Biotin (Figure 2). In order to assess whether we could 
displace MIA-Ru(bpy)3 from the immobilized AR54-Biotin, we treated this complex with 
7.8 M AR54 in solution. In this case, the fluorescence polarization of MIA-Ru(bpy)3 was 
almost identical to the MIA-Ru(bpy)3 free in solution in a well not coated with 
AR54-Biotin. This demonstrates that the molecular mobility is unhindered and that the 
binding is reversible.  
 
 
Figure 2: HTFP assay investigation of interaction of AR54 with MIA-Ru(bpy)3 
In the AR54-Biotin treated well, fluorescence polarization signal increases due to binding of Ru(bpy)3-
labeled MIA protein to immobilized AR54 peptide. After addition of AR54 at a final concentration of 7.8 µM 
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the detected fluorescence polarization of MIA-Ru(bpy)3 is almost identical to the MIA-Ru(bpy)3 free in 
solution in a well not coated with AR54-Biotin, demonstrating that after displacement from immobilized 
AR54-Biotin the molecular mobility is unhindered. 
 
The interaction of MIA with fibronectin has been described.6 In order to test our assay 
concept with this known interaction partner, we applied 30 kDa and 70 kDa proteolytic 
fragments of human fibronectin shown in Figure 3A. As expected, the fluorescence 
polarization decreased upon addition of the fibronectin fragments. Hence, we have 
validated our HTFP assay with the known interactions of MIA protein with AR54 and 
fibronectin and demonstrate that this assay concept is capable of detecting protein 
interactions with a small peptide as well as a 70 kDa protein. 
Additionally, we have performed a titration of MIA-Ru(bpy)3 with 30 kDa fibronectin 
fragment to demonstrate that our assay is also capable of determining binding constants. 
As presented in Figure 3B, we determined a Kd value of 33 nM. The failure of all the 
alternatives as described before led us to conclude that our assay should be beneficial for 
investigating proteins prone to multimerization. Obviously aggregation can lead to artifacts 
in other binding experiments while our assay format circumvents this problem due to the 
long lifetime of the luminescent label.   
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Figure 3: HTFP assay investigation of interaction of 30 kDa and 70 kDa fibronectin fragments with MIA-
Ru-(bpy)3 (A) 30 kDa and 70 kDa proteolytic fragments of human fibronectin, known to interact with MIA 
protein, were applied in the HTFP assay. The fluorescence polarization signal decreases, indicating a 
displacement of MIA protein from AR54-Biotin. (B) Titration of MIA-Ru(bpy)3 with 30 kDa human 
proteolytic fibronectin fragment. The observed Kd is 33 nM. All experiments were performed in triplicates. 
 
4.2.3.2 Buffer additives and detergent controls 
We envisioned this system to act as a screening platform for the identification of potential 
MIA protein inhibitors and further applications. Accordingly, we investigated the influence 
of various buffer additives and detergents commonly used in molecular biology. As 
expected, the addition of 0.1% Triton X-100 or 0.1% 2-mercaptoethanol disrupted the 
interaction of MIA-Ru(bpy)3 and AR54-Biotin (data not shown). While DMSO, which is 
often used in inhibitor screening for dissolving compound libraries, could be tolerated for 
concentrations of up to 2.5%, the addition of 50 mM EDTA induced to a significant 
decrease in FP signal (data not shown). This can be explained by a photoinduced redox 
reaction involving the luminescent label Ru(bpy)3 and EDTA.23 A similar decrease was 
also observed in the absence of AR54-Biotin, further indicating such an interaction. 
 
4.3.2.3 Multimerization studies 
Considering the aggregation of MIA protein, we explored the capabilities of the HTFP 
assay to investigate this phenomenon (Figure 4A). The addition of an excess of unlabeled 
MIA protein to MIA-Ru(bpy)3 proves that the size of the multimers does not change and 
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that there are no aggregates consisting of about ten or more molecules. We estimate this 
from the lifetime of the label and the molecular weight of the protein by the Perrin 
equation.24 To prove the existence of smaller aggregates, we coated wells with a MIA-
Biotin conjugate. Indeed, a large increase in fluorescence polarization was detected, 
indicating the presence of direct MIA-MIA interactions. The formation of multimeric 
structures of MIA protein was also confirmed by Western blot analysis as shown in Figure 
4B. These aggregates appear to be extraordinarily stable since they can even be observed 
after treatment with denaturing and reducing Laemmli buffer at 70°C. 
 
 
 
 
Figure 4: HTFP assay investigation of MIA protein aggregation  
(A) Analysis of MIA aggregation was performed under physiological conditions using DPBS buffer in an 
AR54-uncoated well. The addition of an excess of unlabeled MIA protein proves that there are no aggregates 
formed consisting of about ten or more molecules, as estimated from the lifetime of the label and the 
molecular weight of the protein. We then coated wells with a MIA-Biotin conjugate to prove the existence of 
smaller aggregates and observed a large increase in fluorescence polarization, indicating the formation of 
such smaller aggregates. (B) As also demonstrated by Western blot analysis, 11 kDa MIA protein forms 
multimeric structures that seem to be extraordinarily stable since they can not be degraded after treatment 
with denaturing and reducing Laemmli buffer at 70°C for 10 min. All experiments were performed in 
triplicates. 
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4.3 Discussion 
Several methods have been developed for the investigation of protein interactions. While 
surface plasmon resonance (SPR) 25 can also be used for small molecule interactions with 
the help of antibodys, it is still costly due to the usually proprietary chips. Far-Western 
blotting is time consuming and also not suitable for high throughput applications.26 
Furthermore, this method relies on the refolding of the protein to the native conformation 
on the membrane, which may not always be successful. Immunoprecipitation and pull-
down experiments are equally far more time-consuming than fluorescence based 
investigations.27 Binding experiments using the 1-anilino-8-naphthalene sulfonate (ANS) 
probe,28 while well-plate compatible, suffer from the short excitation and emission 
wavelengths. Automated isothermal calorimetry (ITC) measurements offer the advantage 
of label-free detection, but still require relatively large amounts of substance. 
Methods capable of handling high throughput screenings include various types of 
microarrays using enzymes, isotopes or fluorescent labels. However, these techniques 
require special safety precautions, antibodies and washing steps which may lead to cross-
contamination and other artifacts.  
Fluorescence polarization detection is both high throughput capable and self-referenced, 
meaning that no washing steps are required. This is clearly an advantage over the 
traditional ELISA concept. However, traditional homogeneous FP assays are limited by the 
molecular weight of the interaction partner to be investigated due to the short lifetime of 
the required organic fluorophores. We extend this range by immobilizing a known 
interaction partner of MIA protein and labeling of MIA protein with a luminescent 
transition metal chelate. This would not be possible in an assay conducted entirely in 
solution due to the long lifetime. The maximum acceptable molecular weight of the 
interaction partner obviously depends on the decay time of the label on the target. Given 
the decay time of Ru(bpy)3, we estimate from the Perrin equation 24 that interactions with 
binding partners of up to 500 kDa should still be observable, however, that limit could be 
raised by using a transition metal with a longer decay time. A further limitation of our 
assay is the fact that it will be difficult to estimate aggregate sizes from the polarization 
values due to the long decay time. 
The results show that our HTFP assay allows the investigation of protein/small molecule as 
well as protein/protein interactions. As presented for the interaction of MIA protein with 
AR54, this FP assay should also be amenable for the screening of libraries of potential 
drug candidates. Furthermore, the long lifetime of the luminescent transition metal 
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complex label also allows the identification of proteins interacting with other proteins. 
Additionally, our HTFP assay is also suitable for the investigation of protein aggregation 
and compounds cleaving these aggregates. In contrast to traditional homogeneous FP 
assays, interactions with both high and low molecular weight compounds can be 
investigated. This makes it especially useful for proteins prone to forming multimeric 
structures. This tolerance of the HTFP assay for aggregation makes it unique and should 
allow the investigation of proteins which show aggregation-related artifacts in other assays. 
Since our assay format is variously applicable it is conceivable that it also might be used 
for many different analytical or diagnostic applications. It enables the investigation of 
protein complexes for example for cell signaling molecules, transport proteins or 
transcription factors. It could also be used for the identification of an initiator or regulator 
of polymerization reactions for instance for actin or tubulin subunits as existing in dynamic 
processes of the cytoskeleton. This assay may also serve for the identification of activators 
or co-activators for enzymatic reactions as well as for the design of immunoassays in the 
field of serology and diagnostic. Since the HTFP assay is based on a luminescent transition 
metal complex label our assay benefits from all the associated advantages over organic 
fluorophores. While the inherent photostability is obviously convenient, the large Stokes 
shift increases the signal to noise ratio and allows a broader selection of suitable emission 
filters for the spectrometer. Furthermore, the long lifetime of transition metal complex 
labels also opens the possibility of time-gated measurements. This may be employed for 
multi-label experiments with different transition metal complexes with different lifetimes 
which may be resolved regardless of spectral overlap. Complex biological matrices in the 
samples are also tolerable since the autofluorescence of biological material has a very short 
lifetime and can thus be eliminated.  
 
4.4 Materials and Methods 
Cell lines and cell culture conditions 
The melanoma cell line Mel Im, established from a human metastatic tumor sample 
(generous gift from Dr. Johnson, University of Munich, Germany), was used in Boyden 
Chamber invasion experiments. Cells were maintained in DMEM (PAA Laboratories 
GmbH, Austria) supplemented with penicillin (400 U/mL), streptomycin (50 µg/mL), 
l-glutamine (300 µg/mL) and 10% fetal calf serum (Pan Biotech GmbH, Germany) and 
split in 1:5 ratio every three days. 
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Boyden Chamber Invasion Assay 
Invasion assays were performed in Boyden Chambers containing polycarbonate filters with 
8 µm pore size (Neuro Probe, Gaithersburg, MD, USA) essentially as described 
previously.29 Filters were coated with matrigel, a commercially available reconstituted 
basement membrane (diluted 1:3 in H2O; BD Bioscience, Bradford, MA, USA). The lower 
compartment was filled with fibroblast-conditioned medium used as a chemo attractant. 
Mel Im melanoma cells were harvested by trypsinization for 2 min, resuspended in DMEM 
without FCS at a density 2.5 x 104 cells/mL, and placed in the upper compartment of the 
chamber. Except for the control experiment with untreated cells and experiments where 
cells were only treated with the peptide, MIA protein or Ru(bpy)3-labelled MIA protein, 
respectively, was added to the cell suspension at a final concentration of 200 ng/mL. 
Peptide AR54 (sequence: NSLLVSFQPPRAR) was used at a final concentration of 1 µM. 
After incubation at 37°C for 4 h filters were removed. Cells adhering to the lower surface 
of the filter were fixed, stained, and counted. Experiments were carried out in triplicates 
and repeated at least three times. 
 
Protein analysis in vitro (Western blotting) 
MIA protein was denaturated at 70°C for 10 min after addition of reducing and denaturing 
Roti-Load buffer (Roth, Karlsruhe, Germany) and subsequently separated on sodium 
dodecyl sulfate 12.75% polyacrylamid gels (SDS-PAGE) (Invitrogen, Groningen, The 
Netherlands). After transferring the proteins onto a polyvinylidene fluoride (PVDF) 
membrane (BioRad, Richmond, VA, USA), the membrane was blocked using 
3% BSA/PBS for 1 h at RT and incubated with a 1:150 dilution of primary polyclonal 
rabbit anti MIA antibody  (Biogenes, Berlin, Germany) in 3% BSA/PBS overnight at 4°C. 
After washing in PBS the membrane was incubated with a 1:2000 dilution of an alkaline-
phosphate coupled secondary antibody (Chemikon, Hofheim, Germany) for 2 h at RT. 
Finally, after washing steps, immunoreactions were visualized by nitro blue 
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) (Invitrogen. CA, USA) 
staining.  
 
Luminescent labeling of human MIA protein 
Human MIA protein (100 g) was labeled with Ru(bpy)3-isothiocyanate (1 mg) (Active 
Motif Chromeon, Germany) in 640 L bicarbonate buffer pH 9.3 supplemented with 
200 L DMSO required for dissolving the dye. After 50 min, the reaction mixture was 
70 
4   HTFP Assay for Probing Protein Interactions 
 
purified on a size exclusion column (SephadexTM G-25 M PD-10 Desalting column, 
Amersham Pharmacia Biotech, Sweden) and samples of the collected fractions as well as a 
dilution series of unlabeled MIA protein were analyzed by Western blotting as described 
above.  
 
Biotin conjugation of peptide AR54 
0.25 mg of AR54 was dissolved in 30 L of bicarbonate buffer pH 9.3. After addition of 
0.38 mg Biotin-NHS (Calbiochem, USA) in 10 L DMSO the reaction mixture was 
incubated overnight at 4°C. As the NHS-ester was expected to be completely reacted or 
hydrolyzed, no purification was carried out.  
 
Coating of well plates with AR54-Biotin and MIA-Biotin 
Black streptavidin coated 96 well plates (Greiner Bio-one, Germany) with a loading of 
20 pmol streptavidin per well were treated with 20 equivalents AR54-Biotin per mol of 
(tetrameric) streptavidin in PBS pH 7.4. An uncoated control lane was sealed with 
adhesive film to prevent contamination with AR54-Biotin. After addition of AR54-Biotin, 
the entire plate was sealed with adhesive film and incubated for 3 h under agitation. The 
coated lanes were washed five times with PBS pH 7.4 before being air-dried and sealed 
with adhesive film which was removed only immediately before use of each lane.  
MIA-Biotin was prepared as previously reported 6 and used for treating a well plate as 
described above, except that the plate was not dried and used for measurements 
immediately. 
 
Polarization assay setup 
All measurements were performed at room temperature on a Polarstar Optima microplate 
reader (BMG Labtech, Germany). A 390-10 nm bandpass filter was used for excitation 
while a 520 nm longpass filter was used for the emission light. Even though the extinction 
coefficient is higher at longer wavelengths, we chose a shorter excitation wavelength as 
this led to higher polarization values. A MIA-Ru(bpy)3 concentration of 55 fM was used in 
all experiments. A solution volume of 250 L per well was found to give a low standard 
deviation with high signal intensity. Unless otherwise indicated, all measurements were 
performed in DPBS without calcium or magnesium (PAN Biotech GmbH, Germany). 
Addition of components to the wells was done in the following order: interaction partner, 
buffer, MIA-Ru(bpy)3. Owing to different reaction kinetics, measurements were performed 
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every 5 min over a 30 min period. Polarization values are reported relative (P/P0) to the 
value of free MIA-Ru(bpy)3 in solution in a well not treated with AR54-Biotin. All 
reported values are an average of three independent measurements. 
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5 Dissociation of Functionally Active MIA Dimers by Dodecapeptide 
AR71 Strongly Reduces Formation of Metastases in Malignant 
Melanoma 
 
Abstract 
Melanoma inhibitory activity (MIA) protein, secreted by malignant melanoma cells, 
strongly supports formation of metastases through inhibiting cell-matrix interactions. Here, 
we present the molecular mechanism of MIA action and a way of inhibiting its activity. In 
contrast to previous hypotheses, our results revealed that MIA acts as a dimer to reach 
functional activity. Based on this new finding, we screened peptides for their ability to 
inhibit MIA-MIA interaction, resulting in the identification of dodecapeptide AR71. NMR 
spectroscopy confirmed its binding to the dimerization domain while functional analysis in 
vitro revealed complete inhibition of MIA function. Crucially, injecting AR71 i.v. into a 
mouse model of melanoma metastases led to strong reduction of the formation of 
metastases in vivo. These findings provide an excellent basis for rationally designing a 
novel pharmacophore which inhibits MIA dimerization and activity, strongly reduces 
formation of metastases and thus could provide an effective therapy for malignant 
melanoma.  
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5.1 Introduction 
Malignant melanoma is characterized by aggressive local growth and early formation of 
metastasis. In order to identify autocrine growth-regulatory factors secreted by melanoma 
cells, melanoma inhibitory activity (MIA), an 11 kDa protein, strongly expressed and 
secreted by melanocytic tumor cells was purified from tissue culture supernatant of the 
human melanoma cell line HTZ-19.1-2 Today it serves as a reliable clinical serum tumor 
marker for detection of metastatic diseases and monitoring therapy responses of patients 
suffering from malignant melanoma. In addition, MIA plays an important functional role in 
melanoma development and cell invasion as its expression levels directly correlate with the 
capability of melanoma cells to form metastases in syngeneic animals.3-5  
After transcription, MIA mRNA is translated into a 131 amino acid precursor molecule and 
processed into a mature protein consisting of 107 amino acids after cleavage of the 
secretion signal sequence.2 The transport of MIA protein to the cell rear is induced after 
migratory stimuli.6 Following secretion, MIA subsequently binds to cell adhesion receptors 
integrin 41 and integrin 51. In addition, MIA masks their binding sites at ECM 
molecules including fibronectin, laminin and tenascin.3, 7 Consequently, cell adhesion 
contacts are reduced, enabling tumor cells to migrate and invade into healthy tissue, 
resulting in enhanced metastatic potential.  
Previously, the three-dimensional structure of MIA protein was solved by 
multidimensional nuclear magnetic resonance (NMR) spectroscopy and X-ray 
crystallography techniques.8-12 Corresponding data indicated that MIA defines a novel type 
of secreted protein comprising an SH3 domain like fold.  
In the present study we aimed to determine the so far unknown molecular mechanism of 
MIA. By functionally analyzing MIA mutants we demonstrate for the first time that MIA 
achieves functional activity by self assembly. Peptidic dimerization inhibitors were 
identified and analyzed in in vitro and in vivo studies, thus providing an excellent starting 
point for the development of a new inhibitory strategy. Based on these new data presented 
here, the rational design and development of a novel pharmacophore which inhibits MIA 
and thus strongly reduces tumor cell invasion and formation of metastases could provide a 
key element in malignant melanoma therapy. 
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5.2 Results 
5.2.1 MIA protein is functionally active as a dimer  
Although MIA was thought to act as a monomer, recent data suggests that, as detailed 
below, the active form of the protein consists of a dimer. Using the PreBI modeling 
software (http://pre-s.protein.osaka-u.ac.jp/prebi/) for the prediction of the putative dimer 
interface together with the HADDOCK protein-protein docking program, we obtained a 
model of the MIA dimer comprising a head to tail linkage (Figure 1A).13 The dimerization 
interfaces are located around Y30 and at the region K53-L58 in the n-Src loop and the cleft 
next to Q65-A73 in the distal loop. Further supporting our results, the regions determined 
to form the interface have been described as crucial for functional activity in a previous 
mutagenesis study.14 In addition, Western blot analysis of MIA also demonstrates that 
apart from the monomeric species dimers exist.15 We, therefore, aimed to investigate the 
physiological relevance of MIA dimers and the possible correlation between dimerization 
and functional activity. Having identified the most likely positions of the dimerization 
interfaces, mutants of MIA were tested for their capability to form dimers by Western blot 
analysis (Figure 1B). MIA mutants were expressed in an in vitro transcription/translation 
system. All mutants showed correct folding as evidenced by a MIA-ELISA and were 
selected as not carrying a mutation in the dimerization regions, apart from G61R.14 
Recombinant wt MIA and all mutants clearly show a dimer band except for G61R. 
Interestingly, all mutants but G61R are functionally active in Boyden chamber invasion 
assays, as presented in Figure 1C. MIA wt (RTS) and mutants D29G/Y69H, V46F/S81P, 
T89P and K91N can exhibit this effect to the same extent while MIA mutant G61R 
completely loses activity. The sites of mutations not affecting functional activity (Figure 
1D, depicted in grey) are located outside the dimerization regions, whereas G61R (Figure 
1D, depicted in magenta) is buried in the dimerization cleft (depicted in red) in close 
proximity to the distal loop.  
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Figure 1: MIA protein is functionally inactive as a monomer 
(A) Structure of the MIA dimer according to shape complementarity analyses. The MIA dimer is 
characterized by a head-to-tail orientation, with the dimerization domains consisting of the n-Src loop and the 
cleft next to the distal loop. (B) Western blot analysis of MIA assessing their ability to form dimers. The first 
lane shows recombinant wt MIA, followed by the same protein in an unpurified RTS expression system (wt) 
and mutants D29G/Y69H, V46F/S81P, T89P, K91N and G61R. All homologues, except for G61R, clearly 
show a dimer band. (C) Correlation between dimerization and functional activity revealed that all MIA 
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mutants capable to dimerize are functionally active in Boyden chamber invasion assays as reflected by a 
reduction in the number of invaded cells due to interference with cell adhesion. Mutant G61R, which does 
not form protein dimers does not show any MIA induced effect. (D) NMR structure of MIA showing the 
dimerization domains and the mutation sites. The dimerization domains in the n-Src loop and next to the 
distal loop are depicted in blue and red, respectively. Mutation sites which do not influence dimerization and 
functional activity are shown in grey and obviously lie outside the dimerization domains. The site of 
mutation G61R, which is in direct contact with the dimerization domain next to the distal loop, is shown in 
magenta. This figure was generated using PyMol (Delano, W. L., The PyMol Molecular Graphics System 
(2002) Delano Scientific, Palo Alto, CA, USA). 
 
5.2.2 Peptide AR71 prevents MIA protein dimerization  
We then aimed to identify peptides inhibiting MIA dimerization in a newly developed 
heterogeneous transition-metal based fluorescence polarization (HTFP) assay.15 First, 
MIA-MIA interaction was confirmed using this assay. Here, we immobilized a MIA-biotin 
conjugate in a streptavidin-coated well plate and added MIA labelled with the luminescent 
transition-metal complex Ru(bpy)3. As depicted in Figure 2A, a significant increase in FP 
signal in the wells coated with MIA-biotin was observed compared to control wells not 
functionalized with MIA-biotin. This was attributed to the severely restricted rotational 
mobility of MIA-Ru(bpy)3 bound to the immobilized MIA-biotin.   
We then screened peptides, previously identified by phage display and known to generally 
bind to MIA11, for their potential to prevent MIA dimerization and induce dissociation of 
already existing protein dimers using the HTFP assay. As shown in Figure 2A, peptide 
AR71 (sequence: Ac-FHWRYPLPLPGQ-NH2) was found to be particularly potent in 
dissociating MIA dimers which led to a decrease in FP signal due to increased rotational 
diffusion of the dissociated monomeric MIA-Ru(bpy)3. This effect of AR71 was 
confirmed by Western Blot analysis (Figure 2B). Preincubation of MIA with 1 µM peptide 
AR71 leads to a strong reduction of the dimer bands compared to the control lane or other 
MIA-binding peptides used (AR68, AR69).  
To prove that AR71 functionally inhibits MIA, Boyden chamber invasion assays were 
performed (Figure 2C). In these in vitro experiments, MIA interferes with the attachment 
of cells to matrigel, as reflected by a decrease in cell invasion. After external treatment 
with MIA, invasion of Mel Im cells is significantly reduced about 40% to 50% compared 
to untreated control cells. Pre-incubation of MIA with the inhibitory peptide AR71 results 
in a complete neutralization of the effect caused by MIA, as reflected in the number of 
invaded cells. Treatment of cells with peptide AR71 alone does not influence the migratory 
behaviour of melanoma cells.  
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Figure 2: Peptide AR71 prevents MIA dimerization 
 (A) Heterogeneous transition-metal based fluorescence polarization (HTFP) assay for probing AR71 for its 
ability to directly interfere with MIA-MIA interaction. In the control lanes the FP signal of MIA-Ru(bpy)3 
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was measured in a well coated with MIA-biotin compared to an uncoated well. The significant increase in FP 
in the well coated with MIA-biotin indicates binding of MIA-Ru(bpy)3 to the immobilized MIA-biotin. The 
binding of MIA-inhibitory compound AR71 promotes dissociation of MIA dimers and displaces the surface-
bound MIA-Ru(bpy)3, as reflected by a decrease in fluorescence polarization signal. Peptides AR68 and 
AR69, also derived from phage display, do not interfere with MIA-MIA interaction. (B) Western Blot 
analysis of MIA incubated with 1 µM AR71 demonstrates peptide-induced dissociation of the dimer, as 
deduced by a strong reduction of the dimer bands compared to the control lane. MIA-binding peptides AR68 
and AR69 do not lead to reduced dimer formation. (C) Boyden chamber invasion assays using the human 
melanoma cell line Mel Im indicate that AR71 almost completely inhibits MIA activity. Interference of MIA 
with cell attachment to matrigel results in a decrease in cell invasion; after external treatment with MIA 
invasion of Mel Im cells is significantly reduced about 40% to 50% compared to untreated control cells. Pre-
incubation of MIA with the respective inhibitory peptide results in a complete neutralization of the MIA 
effect. The two control lanes confirm that AR71 alone does not influence the migratory behaviour since 
exposure of cells to the peptide in absence of MIA does not alter the quantity of migrated cells. 
 
5.2.3 MIA interacts with AR71 
After demonstrating the potential of AR71 to inhibit MIA function in in vitro models, we 
could show by multidimensional NMR spectroscopy that MIA binds to this peptide ligand. 
In addition, the potential binding site of AR71 was identified using 15N labeled MIA and 
unlabeled peptide. By using increasing amounts of AR71 peptide, the induced chemical 
shift changes of the MIA 1HN and 15NH resonances were classified according to the degree 
of the combined chemical shift perturbations. Further analysis of the solvent accessibility 
(with a threshold of 20 %) and cluster analysis of the residues effected by peptide binding 
reveals that the binding interface potentially comprises residues C17, S18, Y47, G66, D67, 
L76, W102, D103 and C106 of MIA (Figure 3A) It can therefore be assumed that the 
peptide predominantly binds to the binding site depicted on the left side of Figure 3A, 
whereas the opposite side of the molecule most probably does not participate in binding.  
 
After stably transfecting B16 mouse melanoma cells with a secretion-signal containing 
AR71-HisTag construct (Sig-AR71-HisTag), we first analysed expression and localization 
of endogenous AR71-HisTag peptide. Co-staining of MIA protein and AR71-HisTag 
revealed a colocalization in close proximity to the nucleus. Immunofluorescence studies 
show the localization of MIA (green, Figure 3Ba) and AR71-HisTag (for demonstrating 
colocalization with MIA, the red TRITC emission has been changed to yellow in this false-
color illustration, Figure 3Bb). The colocalization, depicted in red, is indicated by white 
arrows in Figure 3Bc. The excess of MIA not colocalized with AR71 is due to 
internalization of exogenous MIA protein by the melanoma cells.16 Figure 3Bd shows the 
corresponding mock control.  
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Figure 3: Chemical shift differences of MIA upon titration with the dodecapeptide AR71 
(A) Most significant chemical shift differences projected onto the van der Waals surface of MIA upon 
titration with the peptide AR71 are shown in red. The binding site is located in the dimerization domain next 
to the distal loop (compare Figure 1D). This figure was generated using PyMol (Delano, W. L., The PyMol 
Molecular Graphics System (2002) Delano Scientific, Palo Alto, CA, USA). (B) Immunofluorescence studies 
of murine B16 melanoma cells stably transfected with a (Sig)-AR71-HisTag construct. While a) shows MIA 
(FITC) and b) displays AR71-HisTag (TRITC with color changed from red to yellow for better visualization 
of colocalization), colocalization shown in red is indicated by white arrows in c). d) Corresponding mock 
control without AR71-HisTag.  
 
5.2.4 Effect of MIA inhibitory peptide AR71 on formation of metastases in vivo 
MIA expression levels of malignant melanoma cells strictly correlate with a highly 
invasive phenotype in vitro and in vivo.17-19 Further, in vivo studies have demonstrated the 
strong contribution of MIA for melanoma cell invasion and migration.4-5 
In order to assess the ability of peptide AR71 to inhibit the formation of metastases by 
generating inactive MIA monomers in vivo, a previously developed metastasis assay was 
employed.20 In this assay, melanoma cells metastasize from the primary tumor in the 
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spleen via the portal vein into the liver. Nine days after injection of the cells into the 
spleen, the mice were sacrificed, the livers were resected and tissue sections were prepared. 
Here, we used the stably transfected murine B16 melanoma cells with a Sig-AR71-HisTag 
containing construct. In vitro analysis by Boyden chamber assay confirmed that migration 
is drastically reduced in Sig-AR71-HisTag expressing cell clones compared to mock 
control cells (Figure 4A). The interference of AR71-HisTag with MIA-MIA interaction 
was also confirmed in the HTFP assay using wells coated with MIA-biotin (data not 
shown). Subsequently, a Sig-AR71-HisTag clone as well as a corresponding mock control 
was injected into the spleen of C57Bl6 mice, respectively. Histological analysis of 
haematoxylin and eosin stained liver sections revealed that mice being injected with Sig-
AR71-HisTag clones comprised significantly fewer metastases than the mock control 
(Figure 4B). Four representative histological liver sections (hematoxylin and eosin stained) 
of mice injected with the B16 mock control or mice injected with the Sig-AR71-HisTag 
expressing cell clone, respectively, are shown in Figure 4C. Black arrows indicate the 
small metastases in the mock control which are exceedingly reduced in the liver of mice 
injected with the Sig-AR71-HisTag expressing cell clone. No adverse effects of AR71 on 
other organs and tissues were observed. 
These results prompted us to investigate whether AR71 peptide could also reduce the 
formation of metastases when given as an i.v. administration treatment. Therefore, wild 
type murine B16 melanoma cells were injected into the spleen of C57Bl6 mice with the 
mice being subsequently treated with i.v. injections of AR71 (50 g every 24 h). After nine 
days, the mice were sacrificed, the livers were resected and again tissue sections were 
prepared. Histological analyses revealed a significant reduction of the average number of 
metastases in the liver of mice treated with AR71 compared to the liver of untreated 
control mice, as shown in figure Figure 4D. Four representative histological liver sections 
(hematoxylin and eosin stained) of untreated and treated mice, respectively, are shown in 
Figure 4E. Again no adverse effects on other organs and tissues were observed.  
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Figure 4: Effect of MIA inhibitory peptide AR71 on formation of metastases in vivo 
 (A) Murine B16 melanoma cells stably transfected with a (secretion-signal)-AR71-HisTag containing 
construct were analyzed for their migratory activity in a Boyden chamber assay. Compared to the mock 
control, migration is drastically reduced in the two Sig-AR71-HisTag expressing cell clones clone K2 and 
clone K4. (B) Sig-AR71-HisTag clone K4 as well as a corresponding mock control were injected into the 
spleen of Bl/6N mice, respectively. Histological analysis of haematoxylin and eosin stained liver sections 
revealed that mice being injected with Sig-AR71-HisTag clones comprised significantly fewer metastases 
than the mock control. (C) Representative histological liver sections (hematoxylin and eosin stained), two of 
mice injected with the B16 mock control (a and a’) and two of mice injected with the Sig-AR71-HisTag 
expressing cell clone K4 (b and b’). Black arrows indicate small metastases. (D) Wild type murine B16 
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melanoma cells were injected into the spleen of Bl/6N mice with the mice being subsequently treated with 
i.v. injections of AR71 (50 g every 24 h). Histological analyses revealed a significant reduction of the 
average number of metastases in the liver of mice treated with AR71 compared to the liver of untreated 
control mice. (E) Representative histological liver sections (hematoxylin and eosin stained), two of untreated 
(a and a’) and two of treated mice (b and b’). 
 
5.3 Discussion  
Primary melanomas often reach a high proliferation rate and acquire competence for 
metastasis in early stages of the disease. As already presented in previous studies, MIA 
plays a fundamental role in this process.3-4 However, hitherto the molecular mechanism by 
which MIA enables tumor cell release from the primary tumor and promotes formation of 
metastases elsewhere in the body was poorly understood. 
Here, we newly describe that MIA is active as a dimer. MIA dimerization is supported by 
in silico studies as well as Western blot analysis, mutagenesis studies and HTFP assay 
measurements.15 We identified the probable dimerization domains as being located in the 
n-Src loop and in the cleft next to the distal loop. Additionally, this tendency of MIA to 
form homomeric linkages was also indicated by previous NMR spectroscopy experiments 
revealing a transversal relaxation time (T2) shorter than expected for an 11 kDa 
protein.10, 21  
However, until now, dimerization of MIA has not been correlated with functional activity. 
Our studies revealed that MIA is functionally inactive as a monomeric species and only 
wt MIA and MIA mutants still forming dimers were found to be functionally active in 
Boyden chamber invasion assays. The mutants D29G/Y69H, V46F/S81P, T89P and K91N 
are still able to dimerize. Replacement of these amino acids outside the dimerization 
domains in the n-Src loop and next to the distal loop does not hinder dimerization and 
consequently does not influence functional activity. In contrast, the mutation G61R is 
located at the dimerization interface next to the distal loop of MIA. In this mutant, glycine, 
an uncharged amino acid residue with minimum sterical demand is replaced by arginine, a 
positively charged and very large residue. As expected, this exchange strongly impacts 
formation of MIA dimers due to sterical demand and charge repulsion between the two 
respective MIA-MIA binding sites. The fact that monomeric MIA is functionally 
completely inactive suggests that the active site for integrin and ECM binding could 
potentially be generated by self assembly of two identical MIA subunits.  
The concept of proteins that require dimerization in order to reach functional activity has 
been described for example for lipoprotein lipase which is converted into inactive 
monomers by angiopoietin-like protein 4. Concomitant with dissociation of functionally 
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active dimers into monomers, an irreversible loss of catalytic activity was found.22 
Furthermore, this functional coupling between oligomerization and activity of proteins has 
also been reported for herpesvirus protease, which is also inactivated after dimer 
disruption.23-24  
The feasibility of inhibiting protein activity via preventing dimerization was discussed in a 
study by Wlodawer et al. describing a similar mechanism for inhibiting HIV-1 protease, a 
homodimeric protein. requiring dimerization for activation.25 The inhibition is achieved by 
targeting the dimerization interface using peptides promoting dissociation.26 The design of 
small molecules intended to disrupt the dimer and /or bind to an inactive protein monomer, 
therefore, offers an alternative to the strategy of targeting of the active site. 
In our search for MIA inhibitory compounds, we employed the HTFP assay as a rapid 
screening platform to identify peptides that prevent the assembly of inactive monomers to 
functionally active MIA dimers. The dodecapeptide AR71 was found to exhibit significant 
MIA inhibitory effect in in vitro experiments. As reflected by the HTFP assay and Western 
Blot analysis, inhibitory peptide AR71 promotes dissociation of MIA aggregates, while our 
NMR investigations revealed it to directly bind to the dimerization domain next to the 
distal loop.  
Having demonstrated the inhibitory effect of AR71 in the in vitro models, we employed an 
established in vivo metastasis assay to evaluate the capability of peptide AR71 to prevent 
the formation of metastasis of malignant melanoma by inhibiting MIA.20 In our first 
model, Sig-AR71-HisTag expressing B16 cell clones and the respective mock control cells 
were analyzed for their metastatic potential. With the addition of an N-terminal secretion 
sequence ensuring peptide processing into the endoplasmic reticulum, we expected 
subsequent binding and thus inactivation of MIA by preventing formation of functionally 
active protein dimers directly at the location of protein biosynthesis. In 
immunofluorescence studies we could observe this colocalization of MIA and AR71-
HisTag in the cells. In an in vivo mouse model, the expression of AR71 by the stably 
transfected B16 cells led to a dramatic reduction in the formation of metastases compared 
to mock control, again reflecting the need for MIA to form dimers to reach functional 
activity. 
Even though peptides are generally quickly degraded in vivo by proteases and renally 
cleared, we also observed a significant reduction in the formation of metastases in an in 
vivo injection model of AR71. Again, the particularly strong reduction in the number of 
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metastases proves the potency of AR71 to suppress the metastatic spread of melanoma 
cells in vivo.  
To conclude, we have contributed to the understanding of the molecular function of MIA 
by in vitro studies which included multidimensional NMR spectroscopy. These 
investigations revealed that MIA is functionally active as a dimer. By specifically 
screening MIA-binding peptide ligands for their ability to prevent MIA dimerization, we 
identified dodecapeptide AR71 and demonstrate the potency of this peptide to significantly 
reduce the formation of metastases of murine B16 malignant melanoma cells in vivo. This 
study details the mechanism by which peptide AR71 inhibits MIA mediated metastatic 
spread of tumor cells and provides a novel leading structure for the design of potent 
therapeutics for the treatment of malignant melanoma. To overcome the drug resistance 
observed with current treatments, this new strategy of dimerization inhibitors may be 
useful for prevention or at least reduction of metastastatic spread in early stages of the 
disease. Specifically inhibiting the formation of metastases should provide a very effective 
therapy since malignant melanoma is not fatal because of the primary tumor but because of 
organ failure due to formation of metastases. In addition, most conventional treatments still 
affect cancer cells as well as other fast-dividing cell types, resulting in the desire for a 
more targeted therapy. By targeting MIA, which is only expressed in malignant melanoma 
and in early-phase differentiating chondrocytes, the adverse reactions of treatment with 
MIA inhibitory compounds should be minimal. Side effects on cartilage are not expected 
since MIA-deficient mice show no phenotype changes, as previously demonstrated.27  
We feel that this study provides an excellent starting point for the development of a new 
strategy in malignant melanoma therapy. Targeting MIA leads to strongly reduced tumor 
cell invasion and formation of metastases and thus provides a new concept of therapeutic 
intervention. 
 
5.4 Materials and methods 
Cell lines and cell culture conditions 
The melanoma cell line Mel Im, established from a human metastatic bioptic sample 
(generous gift from Dr. Johnson, University of Munich, Germany) was used in all 
experiments. Additionally, main experiments were also conducted using the human cell 
line Mel Ju and the murine cell line B16, which were derived from metastases of malignant 
melanoma. All cells were maintained in DMEM (PAA Laboratories GmbH, Cölbe, 
Germany) supplemented with penicillin (400 U/mL), streptomycin (50 µg/mL), 
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l-glutamine (300 µg/mL) and 10% fetal calf serum (Pan Biotech GmbH, Aidenbach, 
Germany) and split in 1:6 ratio every 3 days. 
 
Protein analysis in vitro (Western blotting) 
Protein samples were denaturated at 70°C for 10 min after addition of reducing and 
denaturing Roti-Load buffer (Roth, Karlsruhe, Germany) and subsequently separated on 
sodium dodecyl sulfate 12.75% polyacrylamid gels (SDS-PAGE) (Invitrogen, Groningen, 
The Netherlands). In the multimerization studies, MIA protein (1 µg) was incubated with 
AR71 (2.5 µg) overnight at RT before being treated as decribed above. After transferring 
the proteins onto a polyvinylidene fluoride (PVDF) membrane (BioRad, Richmond, VA, 
USA), the membrane was blocked using 3% BSA/PBS for 1 h at RT and incubated with a 
1:150 dilution of primary polyclonal rabbit anti MIA antibody (Biogenes, Berlin, 
Germany) in 3% BSA/PBS overnight at 4°C. After washing in PBS the membrane was 
incubated with a 1:2000 dilution of an alkaline-phosphate coupled secondary antibody 
(Chemikon, Hofheim, Germany) for 2 h at RT. Finally, after washing steps, 
immunoreactions were visualized by nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl 
phosphate (NBT/BCIP) (Invitrogen, Karlsruhe, Germany) staining.  
 
Boyden Chamber Invasion Assay 
Invasion assays were performed in Boyden Chambers containing polycarbonate filters with 
8-µm pore size (Neuro Probe, Gaithersburg, MD, USA) essentially as described 
previously.14 Filters were coated with matrigel, a commercially available reconstituted 
basement membrane (diluted 1:3 in H2O; BD Bioscience, Bradford, MA, USA). The lower 
compartment was filled with fibroblast-conditioned medium used as a chemo attractant. 
Mel Im melanoma cells were harvested by trypsinization for 2 min at RT, resuspended in 
DMEM without FCS at a density 2.5 x 10
4 
cells/mL, and placed in the upper compartment 
of the chamber. Except for the control experiment with untreated cells and experiments 
where cells were only treated with the respective peptide, MIA was added to the cell 
suspension at a final concentration of 200 ng/mL. Peptide AR71 (sequence: 
Ac-FHWRYPLPLPGQ-NH2) was used at a final concentration of 1 µM. MIA expressing 
murine B16 melanoma cells stably co-transfected with Sig-AR71-HisTag containing 
pCMX-PL1 vector and an antibiotic resistance comprising plasmid (pCDNA3), and the 
respective mock control were also investigated for their ability to migrate.28 Therefore, 
cells were harvested by trypsinization for 2 min at RT, resuspended in DMEM without 
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FCS at a density 2.5 x 104
 
cells/mL, and placed in the upper compartment of the chamber. 
After incubation at 37°C for 4 h filters were removed. Cells adhering to the lower surface 
of the filter were fixed, stained, and counted. Experiments were carried out in triplicates 
and repeated at least three times. 
 
Coating of well plates with MIA-Biotin 
Black, streptavidin coated 96 well plates (from Greiner Bio-one, Frickenhausen, Germany) 
were coated with MIA-Biotin as described previously.7, 15 An uncoated control lane was 
sealed with adhesive film to prevent contamination. The MIA-Biotin coated plate was used 
for measurements immediately.  
 
Polarization assay setup 
All measurements were performed at RT on a Polarstar Optima microplate reader (BMG 
Labtech, Offenburg, Germany). A 390-10 nm bandpass filter was used for excitation while 
a 520 nm longpass filter was used for the emission light. Even though the extinction 
coefficient is higher at longer wavelengths, we chose a shorter excitation wavelength as 
this led to higher polarization values. MIA-Ru(bpy)3 was prepared and tested for 
functional activity as described previously.15 A MIA-Ru(bpy)3 concentration of 55 fM was 
used in all experiments. A solution volume of 250 L per well was found to give a low 
standard deviation with high signal intensity. All measurements were performed in DPBS 
without calcium or magnesium (PAN Biotech GmbH, Aidenbach, Germany). Addition of 
components to the wells was done in the following order: inhibitory peptide, buffer, 
MIA-Ru(bpy)3. Owing to different reaction kinetics, measurements were performed every 
5 min over a 30 min period. Polarization values are reported relative (P/P0) to the value of 
free MIA-Ru(bpy)3 in solution in a well not treated with MIA-biotin. All reported values 
are an average of three independent measurements.  
 
Cloning Strategy  
Signal-AR71-HisTag pCMX-PL1-plasmid construction: The Signal-AR71-HisTag 
pCMX-PL1 expression plasmid was created by PCR amplification of the human 
hydrophobic signal-peptide sequence, responsible for transport into the endoplasmic 
reticulum, from a Signal-MIA containing expression plasmid using the MJ Research 
PTC-200 Peltier Thermo Cycler (BioRad, Munich, Germany). The HisTag sequence was 
inserted at the C-terminal end of the AR71 peptide using the primers 5’- GAC GAA TTC 
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ATG GCC CGG TCC CTG GTG - 3’ and 5’- GAC AAG CTT TCA GTG ATG GTG 
ATG GTG ATG CTG GCC GGG CAA GGG CAA GGG GTA TCT CCA GTG GAA 
CCT GAC ACC AGG TCC GGA GAA -3’. After amplification of the Signal-AR71-
HisTag fragment, the PCR product was digested with EcoRI and HindIII (NEB, Frankfurt, 
Germany) The insert was purified by gel extraction (Qiagen, Hilden, Germany) and cloned 
into the EcoRI and HindIII sites of the eukaryotic expression vector pCMX-PL1 which 
was previously purified and prepared for ligation using T4-Ligase (NEB, Frankfurt, 
Germany).28 After transformation in DH10ß cells (NEB, Frankfurt, Germany) according to 
the manufacturer´ s instructions, the plasmid was isolated using the MIDI Kit (Qiagen, 
Hilden, Germany) and quantified by a gene quant II RNA/DNA Calculator (Pharmacia 
Biotech, Nümbrecht, Germany). The sequence of the PCR-generated clone was confirmed 
by DNA sequencing.  
 
Stable transfection of murine B16 melanoma cells 
For transfection, 1.5 x 105 cells/mL were seeded in 6-well plates (Corning Omnilab, 
Munich, Germany) and cultured in 2 mL of Dulbecco’s modified Eagle’s medium (PAA, 
Cölbe, Germany) with 10% fetal calf serum (Pan, Aidenbach, Germany). Cells were 
transfected with 0.8 µg of the respective control or His-tagged AR71 containing 
pCMX-PL1 vector and 0.2 µg pcDNA3 providing geneticin (Invitrogen, Karlsruhe, 
Germany) resistance using the LipofectaminPlus (Invitrogen, Karlsruhe, Germany) method 
according to the manufacturer’s instructions. After selection of cells comprising antibiotic 
resistance we confirmed expression and localization of AR71 peptide on mRNA and 
protein level by PCR and immunofluorescence, respectively. 
 
Recombinant expression of MIA and mutant forms 
In vitro protein expression reactions of recombinant human MIA and its mutants were 
performed with the Rapid Translation System RTS 500 E. coli HY Disulfite Kit (Roche, 
Mannheim, Germany) according to the manufacturer’ s instructions. All reactions were 
carried out over night at 30°C or 25°C with efficient stirring in the RTS 500 instrument. 
MIA mutants were checked for correct folding and function as previously described.14 
 
NMR Spectroscopy  
All spectra were recorded at 300 K and pH 7 on a Bruker DRX600 spectrometer equipped 
with a pulsed field gradient triple resonance probe. Water suppression in experiments 
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recorded on samples in H2O was achieved by incorporation of a Watergate sequence into 
the various pulse sequences.29-31 2D 1H-15N HSQC spectra with reduced signal loss due to 
fast  exchanging protons were recorded using procedures described previously.32 All 
spectra were processed with NMRPipe and analyzed with NMRView.33-34 Data handling 
was performed with NMRView. Structure visualisation and superimpositions were done 
with PyMol (Delano, W. L., The PyMol Molecular Graphics System (2002) Delano 
Scientific, Palo Alto, CA, USA). 
 
Dimer model 
The PreBI modeling software (http://pre-s.protein.osaka-u.ac.jp/prebi/) was used together 
with the published X-ray structure of MIA (PDBid: 1I1J) for the prediction of the putative 
dimer interface. Employing the monomeric NMR structure of MIA (PDBid: 1HJD) 
together with the interface information obtained in the previous step a three-dimensional 
model of the dimeric complex was calculated. Computations were performed using the 
data driven protein-protein docking program HADDOCK.13 
 
Protein binding studies 
The NMR titration of MIA with AR71 consisted of monitoring changes in chemical shifts 
and line widths of the backbone amide resonances of uniformly 15N-enriched MIA samples 
as a function of ligand concentration.35-38  
 
In vivo metastasis assay  
To determine the effect of peptide AR71 on the metastatic potential of murine B16 
melanoma cells in vivo, a previously developed mouse metastases model was used.20 
1 x 105 cells of the AR71-HisTag expressing B16 cell clone AR71-His K4 as well as the 
corresponding mock control cells were injected into the spleen of mice (n = 8 for mock 
control cells as well as for AR71-HisTag K4 cells, respectively). After nine days, mice 
were sacrificed, the livers were resected and the number and size of visible black tumor 
nodules on the surface of the livers was noticed. Tissues were fixed in formalin and 
afterwards paraffin embedded sections were hematoxylin and eosin stained for histological 
analysis. 
Additionally, 1 x 105 wt mouse melanoma B16 cells suspended in a solution containing 
AR71 (1 mg/mL) and 0.9% NaCl, or NaCl alone for the control mice, respectively, were 
injected into the spleen of each animal (n = 8 for treated mice, as well as for control 
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without AR71). Peptide AR71 was injected i.v. (50 g every 24 h). After nine days, the 
mice were sacrificed and the livers were excised. Following formalin fixation, tissues were 
embedded in paraffin. Afterwards, sections were prepared and stained using hematoxylin 
and eosin before being subjected to histological analysis. 
 
Immunofluorescence assays 
5 x 105 murine B16 melanoma cells were grown in a 4-well chamber slide (Falcon, BD 
Bioscience, Heidelberg, Germany). After stable transfection with a Sig-AR71-HisTag 
containing expression plasmid and the respective pCMX-PL1 mock control, cells were 
incubated for 48 h at 37°C and 8% CO2. Afterwards, cells were washed and fixed using 
4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 15 min. After 
permeabilization of cells, blocking of non-specific binding sites with blocking solution 
(1% BSA/PBS) for 1 h at 4°C was performed. Cells were incubated with primary 
antibodies rabbit anti-MIA (Biogenes, Berlin, Germany) and mouse anti-HisTag (BD 
Bioscience, Pharmingen, Germany) at a concentration of 1 µg/mL at 4°C for 2 h. After 
rinsing with PBS 5 times, cells were first covered with a 1:200 dilution of the secondary 
antibody TRITC anti-mouse (TRITC-conjugated donkey anti-mouse antibody, Jackson 
Immuno Research Laboratories, West Grove, PA, USA) and FITC anti-rabbit (FITC-
conjugated polyclonal swine anti rabbit immunoglobulin, DakoCytomation, Glostrup, 
Denmark) in PBS at 4°C for 1 h, respectively. Following incubation with primary 
antibodies, cells were washed with PBS and coverslips were mounted on slides using Hard 
Set Mounting Medium with DAPI (Vectashield, H-1500, Linearis, Wertheim Germany) 
and imaged using an Axio Imager Zeiss Z1 fluorescence microscope (Axiovision Rel. 
4.6.3) equipped with an Axio Cam MR camera. Images were taken using 63x oil 
immersion lenses.  
 
Statistical analysis 
In the bar graphs, results are expressed as mean ± S.D. (range) or percent. Comparison 
between groups was made using the Student's unpaired t-test. A p-value <0.05 was 
considered as statistically significant (ns: not significant, *: p<0.05, **: p<0.01, ***: 
p<0.001). All calculations were made using the GraphPad Prism Software (GraphPad 
Software, Inc., San Diego, USA). 
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6 Summary 
 
Melanoma inhibitory activity (MIA), an 11 kDa protein expressed and secreted by 
malignant melanoma cells, plays a key role in development and progression of malignant 
melanoma. It facilitates the release of tumor cells from the primary tumor and thus strongly 
promotes formation of metastases. However, the processing of MIA protein during cell 
migration and the characterization of protein activity on a molecular level has not been 
elucidated so far. 
These studies detail the mechanism by which MIA protein contributes to the aggressive 
and invasive behaviour of malignant melanoma cells. After migratory stimuli of tumor 
cells a directed, microtubule based protein transport to the rear cell pole is induced. MIA 
protein secretion is a Ca2+-dependent process regulated by the calcium activated potassium 
channel KCNN4 (IKCa1). This channel type has previously been reported to be in the 
active state at the rear pole of migrating cells. Following secretion, MIA protein directly 
interacts with cell adhesion receptors, including integrin 41 and 51, and extracellular 
matrix molecules. MIA-integrin-complexes are subsequently internalized into the cell. 
After dissociation of these complexes, MIA protein is degraded in acidic vesicles while 
integrins are transported to the cell front to form new adhesion contacts. Since MIA protein 
secretion is restricted to the cell rear, it mediates localized tumor cell detachment from 
surrounding structures of the primary tumor and enables invasion into healthy tissues.  
At the molecular level, NMR spectroscopy revealed that MIA protein forms homodimers 
with head to tail linkages. As indicated by mutant analysis in Boyden Chamber invasion 
assays and further in vitro protein analyses, MIA protein reaches functional activity via self 
assembly. To inhibit MIA protein function by preventing protein dimerization, 
MIA-binding peptides, which were previously identified in a page display experiment, 
were specifically screened for their ability to dissociate MIA protein dimers. In order to 
conduct this screening, a heterogeneous transition-metal based fluorescence polarization 
assay (HTFP assay) was developed. In this assay format, MIA protein was immobilized in 
a well plate and MIA protein interactions were detected when the addition of Ru(bpy)3-
labeled MIA protein led to an increase in the fluorescence polarization signal. 
Dodecapeptide AR71 dissociated MIA protein assemblies, as evidenced by a strong 
decrease in the fluorescence polarization signal. In addition, Western blot analysis also 
confirmed monomerization of MIA protein after treatment with AR71, while NMR-
spectroscopy revealed that AR71 directly binds to the dimerization domain.  
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By performing Boyden chamber invasion assays functional inhibition of MIA protein by 
peptide AR71 was also demonstrated in vitro. Therefore, the MIA inhibitory effect of 
AR71 was analyzed in a murine melanoma mestastases in vivo model. It was clearly 
demonstrated that treatment with dodecapeptide AR71 strongly reduces the number of 
metastases in vivo. These studies may constitute a foundation for the development of a 
MIA protein inhibitor which could represent a new therapeutic strategy as an antimetastatic 
treatment for malignant melanoma.  
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7 Zusammenfassung 
 
Melanoma inhibitory activity (MIA), ein 11 kDa großes Protein, wird von malignen 
Melanomzellen exprimiert und sekretiert. MIA Protein spielt eine wichtige Rolle bei der 
Entwicklung und Progression des malignen Melanoms. Durch direkte Interaktion mit 
Zelladhäsionsmolekülen und Strukturen der extrazellulären Matrix erleichtert MIA Protein 
das Ablösen von entarteten Zellen aus dem Primärtumorverband und fördert somit die 
Metastasenbildung. Der detaillierte Mechanismus des Proteintransportes während der 
Zellmigration und die Charakterisierung der Proteinaktivität auf molekularer Ebene sind 
jedoch bis heute noch nicht vollständig aufgeklärt.  
Die in dieser Studie erstellten Daten zeigen, auf welchem Mechanismus basierend MIA 
Protein zum aggressiven Verhalten und invasiven Phänotyp der malignen Melanomzellen 
beiträgt. Nach migratorischem Stimulus der Tumorzellen wird MIA Protein, 
eingeschlossen in sekretorischen Vesikeln, entlang von Mikrotubulisträngen gerichtet zum 
hinteren Zellpol transportiert. Die anschließende Proteinsekretion ist ein Ca2+ abhängiger 
Prozess, der vom Calzium-aktivierten Kaliumkanal KCNN4 (IKCa1) reguliert wird. In 
einer bereits veröffentlichten Studie ist beschrieben worden, dass dieser Kanal nur am 
hinteren Zellpol migrierender Zellen im aktiven Zustand ist. Nach der Sekretion bindet 
MIA direkt an Zelladhäsionsrezeptoren wie Integrin 41 und 51, und an extrazelluläre 
Matrixstrukturen. MIA-Integrin-Komplexe werden sofort nach ihrer Bildung internalisiert. 
Nach ihrer Aufnahme dissoziieren die Komplexe, MIA Protein wird in Lysosomen 
abgebaut während Integrine wieder zur Zellfront transportiert werden um dort neue 
Zelladhäsionskontakte bilden zu können. Da sich die MIA Proteinsekretion in 
migrierenden Zellen auf den hinteren Zellpol beschränkt, unterstützt MIA fokales Ablösen 
der Tumorzelle von umgebenden Strukturen und ermöglicht so eine gerichtete Invasion in 
umliegendes gesundes Gewebe.  
Molekulare Protein Analysen mittels NMR-Spektroskopie zeigen, dass MIA ein 
Homodimer mit sogenanntem „head to tail“ Bindungsmotiv bildet. In Western Blot 
Analysen und in vitro Invasions Experimenten mit MIA Mutanten wurde gezeigt, dass 
MIA Protein durch Dimerisierung funktionelle Aktivität erlangt. Um MIA Protein 
funktionell zu hemmen, wurde gezielt nach MIA Protein bindenden Peptiden gescreent, die 
in der Lage sind Dimerisierung zu verhindern bzw. bereits bestehende Dimere 
aufzubrechen und damit das Protein zu inaktivieren.   
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Zur Durchführung eines solchen Screening Experiments wurde ein heterogener 
Übergangsmetall-basierter Fluoreszenz Polarisations Assay (HTFP assay) entwickelt. Für 
diese Untersuchungsmethode wird biotinyliertes MIA Protein in einer Streptavidin 
beschichteten Wellplate immobilisiert. Nach Zugabe von Ru(bpy)3 markiertem MIA 
Protein kommt es zur Protein-Protein Interaktion und damit auch zum Anstiegs des 
Fluoreszenzpolarisationssignals. Das Dodekapeptid AR71 dissoziiert MIA-MIA 
Bindungen und führt zu einer starken Abnahme des Fluoreszenzpolarisationssignals. Auch 
in Western Blot Analysen bestätigt sich, dass MIA Dimere nach Behandling mit Peptid 
AR71 aufgebrochen werden. Die Binding-Site dieses Peptids wurde mittels NMR-
Spektroskopie identifiziert. Sie befindet sich genau in der Dimerisierungsdomäne des MIA 
Proteins. Da Peptid AR71 MIA Protein Aktivität in vitro hemmt, wurde der inhibitorische 
Effekt des Peptids auch in vivo in einem murinen Melanom Metastasen Modell analysiert. 
Die Behandlung der Tiere mit Dodekapeptid AR71 führt zu einer stark reduzierten Anzahl 
der Metastasen. Diese Studien bestätigen, dass MIA Protein ein neues Target Molekül für 
die Behandlung des malignen Melanoms darstellt. Ein MIA Protein Inhibitor könnte einen 
neuen, antimetastatischen Therapieansatz liefern.  
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8 Abbreviations 
ANS   1-anilino-8-naphthalene sulfonate 
Arf6   ADP-ribosylation factor 6 
BCIP   5-bromo-4-chloro-3-indolyl phosphate 
BIMI   bisindolylmaleimide I 
BSA   bovine serum albumin  
COP I   coat protein complex I 
COP II  coat protein complex II 
DAPI   4',6-diamidino-2-phenylindole 
DIEA   N,N-diisopropylethylamine 
DLS   dynamic light scattering 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  dimethylsulfoxide 
ECM   extracellular matrix 
EDTA   ethylenediamine tetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
FCS   fetal calf serum 
FITC   fluorescence-isothiocyanat  
FP   fluorescence polarization 
FRET   fluorescence resonance energy transfer 
HOBt   hydroxybenzotriazole 
HTFP assay  heterogeneous transition metal based fluorescence polarization assay 
ITC   isothermal calorimetry 
kDa   kilo Dalton 
KCNN4  Ca2+-activated K+-channel, subfamily N, member 4 
MBHA  4-methylbenzhydrylamine hydrochloride  
MIA   melanoma inhibitory activity 
MTOC  microtubule organizing center 
MW   molecular weight 
NBT   nitro blue tetrazolium 
NHS   N-hydroxy succinimide 
NMR   nuclear magnetic resonance 
PBS   phosphate buffered saline 
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PCR   polymerase chain reaction 
PKC   protein kinase C 
PVDF   polyvinylidene fluoride 
Rab11   Rab-protein 11, member of the Ras superfamily of GTPases 
RT   room temperature 
Ru(bpy)3  tris(2,2'-bipyridine)ruthenium (II) 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SNARE  soluble N-ethylmaleimide-sensitive-factor attachment receptor 
SPR   surface plasmon resonance 
TBTU O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate 
WT wild type 
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